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1National cervical screening
monitoring indicators
This report monitors the performance of the National Cervical Screening Program using 10
indicators. Indicators are used as summary measures of program activity, performance and
outcome. They help measure changes in disease patterns and examine the contribution health
interventions may have in preventing or reducing deaths. They can also be used to assist in the
evaluation of screening or other health interventions.
Screening indicators for the National Cervical Screening Program cover the areas of
participation, early re-screening, low- and high-grade abnormality detection, incidence and
mortality. The National Advisory Committee and state and territory cervical screening
programs have endorsed these indicators. Indicators are reviewed annually and, in this report,
definitions of Indicators 2 and 5 have been changed compared with the definitions used in
previous reports.
A listing of the 10 indicators and their definitions follows. The target age group for the National
Cervical Screening Program is 20 to 69 years.
Indicator 1: Participation rate for cervical screening
Percentage of women screened, in a 24-month period by 5-year age groups (20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69), for all ages (20+) and the target age
group (20–69 years).
Indicator 2: Early re-screening
Proportion of women re-screened by number of re-screens during a 21-month period following
a negative smear.
Indicator 3: Low-grade abnormality detection
Number of women with a histologically verified low-grade intraepithelial abnormality detected
in a 12-month period as a ratio of the number of women with a histologically verified high-
grade intraepithelial abnormality detected in the same period.
Indicator 4: High-grade abnormality detection
Detection rate for histologically verified high-grade intraepithelial abnormalities per 1,000
women screened in a 12-month period, by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years—age-standardised).
Indicator 5: Incidence of micro-invasive squamous cell carcinoma
Incidence rate of micro-invasive squamous cell carcinoma per 100,000 estimated resident
female population in a 12-month period, by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years—age-standardised).
2Indicator 6: Incidence of squamous, adenocarcinoma, adeno-squamous and
other cervical cancer
Incidence rate of squamous, adenocarcinoma, adeno-squamous and other cervical cancer per
100,000 estimated resident female population in a 12-month period, by 5-year age groups
(20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+)
and for the target age group (20–69 years—age-standardised).
Indicator 7: Mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a
12-month period, by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years—
age-standardised).
Periodic indicators
Periodic indicators have been developed to report on issues that are of importance in
monitoring the outcomes of the cervical screening program over a longer period of time than
1 year. This longer period allows for a greater aggregation of information on issues that are
subject to wide annual fluctuations and allows for a more confident and meaningful estimate of
the outcomes. The periodic indicators presented in this report are based on a reporting period
of 4 years.
Periodic incidence and mortality indicators by location
Indicator 8: Incidence by location
Incidence rate of cervical cancer per 100,000 estimated resident female population in a 4-year
period, by geographic location1 and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years—age-standardised).
Indicator 9: Mortality by location
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year
period, by geographic location1 and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years—age-standardised).
Postcode and statistical local area information for incidence and mortality is routinely collected
at the point of diagnosis or death. These data have been classified using the Rural, Remote and
Metropolitan Areas classification (RRMA). This classification was developed in 1994 by the
then Department of Primary Industries and Energy and the then Department of Human
Services and Health as a framework by which various data sources could be analysed for
metropolitan, rural and remote zones. The RRMA groups are classified according to Statistical
Local Area based on the Australian Standard Geographical Classification (ASGC) version 2.1
(DPIE & DHSH 1994). Concordance algorithms have been developed to convert statistical local
                                                     
1 See Table A for location classified by RRMA.
3area information coded according to earlier and later ASGC versions into rural, remote and
metropolitan area groupings.
Table A: Structure of the Rural, Remote and Metropolitan Areas classification
Zone Category
Metropolitan zone Capital cities
Other metropolitan centres (urban centre population >100,000)
Rural zone Large rural centres (urban centre population 25,000–99,999)
Small rural centres (urban centre population 10,000–24,999)
Other rural areas (urban centre population <10,000)
Remote zone Remote centres (urban centre population >5,000)
Other remote area (urban centre population <5,000)
Source: DPIE & DHSH 1994.
Indicator 10: Indigenous mortality
Death rate from cervical cancer per 100,000 estimated resident female population in a 4-year
period by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years—
age-standardised).
This indicator examines the patterns of mortality among Indigenous women.
Identification of Indigenous status is still very fragmented and generally of poor quality in
health data collections, and cervical screening data are no exception. Of the seven cervical
screening indicators, only one indicator can be stratified by Indigenous status: mortality. Even
for this, coverage is not complete. Only Western Australia, South Australia, the Northern
Territory and Queensland are currently considered to have adequate coverage of Indigenous
deaths in the registration of deaths. Therefore, mortality data from these jurisdictions only are
analysed in this report.
Confidence intervals
Where indicators include a comparison between states and territories, between time periods,
between geographic locations or between Indigenous and non-Indigenous women, a 95%
confidence interval (CI) is presented along with the rates. This is because the observed value of
a rate may vary due to chance even where there is no variation in the underlying value of the
rate. The 95% confidence interval provides a probability that the difference is not due to chance.
Where the confidence intervals do not overlap, there is at least 95% confidence that the change
in a rate is greater than that which could be explained by chance. Where the intervals do
overlap, then there is not a 95% confidence that changes in the rate are due to chance.
For example, the participation rate for New South Wales in 1998–1999 was 60.8% with a
confidence interval of 60.7% to 60.9%. The corresponding rate for 1999–2000 was 60.2% with a
confidence interval of 60.1% to 60.3%. These two intervals do not overlap, so there is at least
95% confidence that the difference between the 1998–1999 and 1999–2000 rates is larger than we
would expect due to chance alone.
Another example is the comparison between cervical cancer mortality rates for women living in
rural and remote areas. In the period 1997 to 2000 there were 2.4 cervical cancer deaths per
4100,000 women living in rural areas. This rate had a confidence interval of 2.2 to 2.6. The
corresponding rate for women in remote areas was 3.7 per 100,000 women, with a confidence
interval of 2.2 to 5.4. These confidence intervals overlap, so despite the relatively large
difference between the two observed rates there is less than 95% probability that these
differences are not caused by chance. This arises from the fact that remote areas of Australia
have small populations, which leads to small numbers of deaths from any specific cause, and
these small numbers may fluctuate from year to year over time. This in turn leads to relatively
wide confidence intervals for an observed death rate.
It is important to note that this result does not imply that the difference between the two rates
is definitely due to chance. Instead, an overlapping confidence interval represents a difference
in rates which is too small to differentiate between a real difference and one which is due to
chance variation.
5Participation
The major objective of the National Cervical Screening Program is to reduce morbidity and
deaths from cervical cancer by detecting treatable pre-cancerous lesions before their
progression to cancer. Through increased participation, more women with pre-cancerous
abnormalities can be detected and treated before progression to cervical cancer, thus reducing
morbidity to women. In addition, increased participation will lead to the detection of more
women with early stages of cancer where treatment can reduce mortality.
The program, through a variety of recruitment initiatives, actively targets women in the age
group 20–69 years. The recommended screening interval for women in the target age group
20–69 years who have ever been sexually active at any stage in their lives is 2 years. Pap smears
may cease at the age of 70 years for women who have had two normal Pap smears within the
last 5 years. Women over 70 years who have never had a Pap smear, or who request a Pap
smear, are screened.
Some women in the target population are unlikely to require screening. They include:
• those who have had a total hysterectomy with their cervix removed;
• those who have never been sexually active; and
• women with a previously diagnosed gynaecological cancer (this last group is monitored
under a clinical arrangement) (Snider & Beauvais 1998).
Participation rate calculations should in principle exclude all three groups from the data. In
practice, the data are adjusted to remove women who have had a hysterectomy but the latter
two groups cannot be excluded due to methodological difficulties.
State and territory Programs have strategic plans in place to increase participation of women in
cervical screening. Such strategies include targeting priority population-groups including
Indigenous women, rural and remote women, and women from culturally and linguistically
diverse backgrounds.
The objective, measurement and usefulness of participation as an indicator is outlined below:
• The participation indicator measures the proportion of the target population covered by the
cervical screening program and the current screening policy of a 2-yearly interval.
• This indicator is important in assessing the contribution of the cervical screening program
to changes in incidence and mortality.
• The indicator can be used as a means of evaluating recruitment practices, particularly if
participation rates are analysed by demographic characteristics.
• When this indicator is used in conjunction with others, it can be used to support analysis
relating to target groups and screening intervals.
• The data presented for this indicator refer to the 2-year period 1999–2000. Data for the
period 1998–1999 are also included for comparison.
6State- and territory-specific issues
• Except for Western Australia and the Australian Capital Territory, the participation rates
are based on all women who were screened in that state or territory. This may lead to an
over-estimation of numbers of women screened because of double counting of some
women between states. This may be the result of difficulty in identifying state of residence
for women in border areas and inclusion of women resident overseas.
• The reference period for this indicator is from 1 January 1999 to 31 December 2000.
Queensland data, however, refer to the 2-year period from March 1999 to February 2001.
This is because the Queensland Pap Smear Register began in February 1999 and therefore
no data are available for the earlier period.
7Indicator 1: Participation rate for cervical screening
Percentage of women screened in a 24-month period, by 5-year age groups (20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the
target age group (20–69 years).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Tables 1b and 2b (pages 40 and 42).
Notes
1. Participation rates have been adjusted for the estimated proportion of women who have had a hysterectomy.
2. These data exclude women who have opted not to be on the register.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 1: Participation rates in the National Cervical Screening Program, by age group, Australia,
1998–1999 and 1999–2000
Age group
2-year period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Per cent)
1998–1999 52.0 66.0 69.7 71.4 70.9 69.9 72.8 63.9 57.4 45.2 64.8
1999–2000 49.5 62.4 67.0 68.7 68.8 67.8 71.3 62.5 56.5 44.2 62.6
Notes
1. The Queensland register began in February 1999; therefore no data were available for the 1998–1999 period.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
8• In 1999–2000, 62.6% of women in the target age group 20–69 years participated in cervical
screening. The proportion of women participating in screening has declined significantly
between the two periods 1998–1999 and 1999–2000. Excluding Queensland data which were
not included in 1998–1999 the proportion of women who participated in screening was
63.3% in 1999–2000, a statistically significant decline from 64.8% in 1998–1999.
• The total number of women screened in Australia in 1999–2000 was 3,314,787, of whom
3,244,329 (98%) were in the target age range of 20–69 years (Table 2a, page 41).
• Participation in screening is highest at the age groups 35–39 to 50–54 but declines sharply
from the age group 55–59.
• Between the two reporting periods, the age-specific participation rates declined in all age
groups. This decline was greatest at younger ages. Screening rates for women aged 25–29
years decreased from 66.0% to 62.4% and for women aged 20–24 years from 52.0% to 49.5%.
9Notes
1. Rates are expressed as the percentage of the eligible female population and age-standardised to the Australian 1991 population.
2. No data were available for Queensland for the period 1998–1999 as the Queensland register began in February 1999.
3. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 2: Participation (age-standardised) in the National Cervical Screening Program by women aged
20–69 years, states and territories, 1998–1999 and 1999–2000
2-year period/
rate NSW Vic Qld(a) WA(b) SA Tas ACT(b) NT Australia
1998–1999
AS rate 60.8 68.9 n.a. 65.4 67.6 66.3 67.6 64.5 64.8
95% CI 60.7–60.9 68.8–69.0 n.a. 65.1–65.6 67.3–67.8 65.8–66.7 67.0–68.1 63.7–65.3 64.8–64.9
1999–2000
AS rate 60.2 66.2 59.5 62.8 66.2 65.5 65.1 65.6 62.6
95% CI 60.1–60.3 66.1–66.3 59.3–59.6 62.6–63.1 66.0–66.5 65.0–65.9 64.6–65.7 64.9–66.4 62.5–62.6
(a) Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
(b) The WA and ACT Registries only register women with a valid WA  or ACT address respectively.
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• In 1999–2000, the proportion of women screened in the target age group of 20–69 years in
states and territories varied from a high of 66.2% in Victoria and South Australia to a low of
59.5% in Queensland.
• Compared to 1998–1999, all jurisdictions except the Northern Territory experienced a
decreased rate of participation in 1999–2000. The rate of decline was statistically significant
in New South Wales, Victoria, Western Australia, South Australia and the Australian
Capital Territory. Queensland had no data for the period 1998–1999.
• The Northern Territory registered an increased participation rate in the target age group,
but the increase is not statistically significant.
• All registers except those in Western Australia and the Australian Capital Territory keep
records of Pap smears for women screened in their jurisdiction but who live outside that
jurisdiction. The largest proportion of interstate women recorded for 1999–2000 was in New
South Wales (0.9% of all women screened in the state).
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Early re-screening
The National Cervical Screening Program seeks to maximise reductions in incidence of and
mortality from cervical cancer. The design of the screening program defines two key
parameters to achieve these objectives—target populations and screening intervals. Compliance
with these parameters is crucial in maintaining the effectiveness of the program and in
maintaining cost efficiency in order that resources may be used to increase population
coverage. For most women who have a negative smear, the recommended interval before their
next screen is 2 years.
This indicator is defined as the repeating of a Pap smear within 21 months of a negative smear
report.
This indicator:
• tracks over a period of 21 months a cohort of women from all states and territories, who
had a negative smear result in February 1999, to determine the extent of early re-screening
within the National Cervical Screening Program. The exception to this is Queensland where
the index month is March. February was selected as the index month nationally because it
has been shown to be a relatively stable month in terms of the number of women who are
screened. This pattern has been consistent over a number of years, partly because fewer
women take holidays at this time;
• measures the compliance with the recommended screening interval following a negative
smear; and
• is important in assessing screening coverage around the recommended interval, as
significant differences may reduce program effectiveness.
This indicator should be interpreted with caution as some early re-screening after a negative
Pap smear report is appropriate and in accordance with the National Health and Medical
Research Council (NHMRC) guidelines. Specifically, if a woman has a history of histologically
proven high-grade abnormality, then annual screening is recommended. If a woman is being
monitored after treatment or during the resolution phase of a low-grade abnormality, it is
appropriate for her to be screened earlier than the 24 months interval.
Data issues
The data published in previous reports for Indicator 2, early re-screening, are not directly
comparable with the data in this report as this indicator has been modified to change the
follow-up period from 24 months to 21 months. This change has been made because women
often have their Pap smear taken at a time convenient to them and are likely to have their
biennial screening immediately before the 24-month anniversary. Also for some women,
prescriptions for oral contraceptives lapse at 22 months and the women are then likely to
combine their Pap smears at their visit to the GP for renewing their scripts for contraceptives.
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Indicator 2: Early re-screening
Proportion of women re-screened, by number of re-screens during a 21-month period
following a negative smear.
Refer to Table 4 (p. 43).
Note:  The reference period for this indicator was the 21 months following the index month February 1999. For Queensland the index month
was March 1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 3: Proportion of women re-screened, by number of screens during the 21-month period
following a negative smear in February 1999, Australia
21-month period 0 screens 1 screen 2 screens 3+ screens
(Per cent)
Feb 1999–Nov 2000 68.0 27.3 3.8 0.9
Note: Previously published data for this indicator refer to a cohort of women followed up for a period of 24 months. Therefore, the data published in
previous reports are not directly comparable to the data published here.
This indicator, early re-screening, tracked over a period of 21 months a cohort of 175,723
Australian women who had a negative smear result in the index month to ascertain how many
of them had early repeat screens.
• Of these women 68% were not re-screened in the follow-up period, 27% had one additional
screening, 3.9% two additional screenings and less than 1% had 3 or more additional
screenings.
13
Refer to Table 4 (p. 43).
Note: The reference period for this indicator was the 21 months following the index month February 1999. For Queensland the index
month was March 1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 4: Proportion of women re-screened, by number of screens during the 21-month period
following a negative smear in February 1999, states and territories
No. of
screens NSW Vic Qld WA SA Tas ACT NT Australia
(Per cent)
0 screens 67.5 66.1 70.8 66.8 70.2 68.9 71.3 70.8 68.0
1 screen 28.3 28.3 24.7 29.1 25.4 26.6 24.0 25.0 27.3
2 or more 4.2 5.6 4.5 4.2 4.5 4.4 4.7 4.2 4.7
• Over 70% of the women in Queensland, South Australia, the Australian Capital Territory
and the Northern Territory who had a negative Pap smear result in the index month had no
additional screenings during the follow-up period of 21 months.
• The lowest proportion of women who had additional smears was in the Australian Capital
Territory (28.7%) and the highest was in Victoria (33.9%).
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Low-grade abnormalities
The Pap smear test is able to identify a range of abnormalities in cervical cells. Some of these
abnormalities (the so-called high-grade abnormalities) have a greater chance of becoming
malignant, and are therefore treated aggressively. The chance of low-grade abnormalities
progressing to malignant change is very much less.
In this report a low-grade intraepithelial abnormality includes:
• atypia;
• warty atypia (human papilloma virus (HPV) effect);
• possible cervical intraepithelial neoplasia (CIN) (see Glossary);
• equivocal CIN;
• CIN 1; and
• endocervical dysplasia not otherwise specified (NOS).
The indicator is measured as the ratio of histologically verified low-grade intraepithelial
abnormalities detected to histologically verified high-grade intraepithelial abnormalities.
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Indicator 3: Low-grade abnormality detection
Number of women with a histologically verified low-grade intraepithelial abnormality
detected in a 12-month period as a ratio of the number of women with a histologically
verified high-grade intraepithelial abnormality detected in the same period.
Refer to Tables 5a and 5b (p. 44).
Note: Data for Queensland were incomplete for 1999 as the Queensland register began in February 1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 5: Ratio of low- to high-grade abnormalities, by women aged 20–69 years, states and territories,
1999 and 2000
Year NSW Vic Qld WA SA Tas ACT NT Australia
(Ratio)
1999 1.4 1.2 n.a. 1.7 1.4 1.4 1.2 0.9 1.4
2000 1.4 1.2 1.6 1.7 1.5 1.4 1.2 1.1 1.4
• The ratio of histologically confirmed low-grade intraepithelial abnormalities to high-grade
intraepithelial abnormalities in Australia in 2000 was 1.4, which was the same as for 1999
(1.4). Excluding Queensland from the 2000 data for a valid comparison, the ratio still
remains at 1.4.
• The ratio of low-grade to high-grade abnormalities in 2000 varied from 1.1 in the Northern
Territory to 1.7 in Western Australia. The younger age structure of the female population in
the Northern Territory is partly responsible for this result as the rate of high-grade
abnormalities found is much higher in women less than 35 years of age (see Indicator 4).
16
• Between the two periods 1999 and 2000, the ratios of low-grade to high-grade abnormalities
increased in South Australia, and in the Northern Territory. In the Northern Territory, in
1999, there were more cases of high-grade than low-grade abnormalities detected but the
reverse was true in 2000.
17
High-grade abnormalities
High-grade lesions have a greater probability of progressing to invasive cancer than low-grade
lesions. Therefore, one of the aims of the National Cervical Screening Program is to set a
screening interval which detects most of these lesions before they progress and become
invasive. This indicator measures the frequency of this type of abnormality in the screened
community. A high-grade intraepithelial abnormality is defined in this report as CIN 1/2,
CIN 2, CIN 3 or adenocarcinoma in situ.
The National Health and Medical Research Council has produced guidelines to assist in the
management of women who have low- and high-grade intraepithelial abnormalities (DHSH
1994b).
State- and territory- specific issues
• The reference period for Indicator 4 was 12 months from January to December 2000 for all
states and territories, except for Queensland where data refer to a 12-month period from
March 2000 to February 2001.
• The Queensland register commenced in February 1999; therefore data for Queensland were
not available for 1998–1999.
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• Of the 1,864,492 women screened in the target age group 20–69 years in 2000, high-grade
intra-epithelial abnormalities were detected in 7.4 per 1,000 women (13,851).
• The age-standardised rate of histologically verified high-grade abnormalities declined from
7.6 per 1,000 women screened in the target age group 20–69 years in 1999 to 7.5 per 1,000
women screened in 2000. Queensland data were not included in 1999, and, when
Queensland was excluded from 2000 data for comparison, the age-standardised rate of
histologically verified high-grade abnormalities for Australia in 2000 was 7.1 per 1,000
women screened, a statistically significant fall from 7.6 per 1,000 in 1999.
• High-grade abnormalities per 1,000 women are highest in the younger ages. For example,
women in the age groups under 35–39 had a rate of high-grade abnormalities of 10 per
1,000 or over. In contrast, the rate of high-grade abnormalities among women in age groups
above 50–54 was less than 2 per 1,000.
• Between the two periods 1999 and 2000 the age-specific rates of high-grade abnormalities
detected decreased in most age groups, in particular, in the older age groups. When
Queensland was excluded, the age-specific rates of high-grade abnormalities detected in
2000 declined further in every age group except in the age groups 60–64 and 65–69 where
the rates remained the same as before.
20
Refer to Tables 9a and 9b (p. 51).
Notes
1. The Queensland Health Pap Smear Register began operations in February 1999; therefore, no data were available for 1999.
2. The reference period for this indicator is from January to December 2000; for Queensland, it is from March 2000 to February 2001.
3. Rates are standardised to the 1991 Australian total population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Figure 7: Age-standardised rate of high-grade abnormalities per 1,000 women screened aged
20–69 years, states and territories, 1999 and 2000
AS rate NSW Vic Qld WA SA Tas ACT NT Australia
1999 7.7 6.9 n.a 7.7 8.5 9.9 6.8 8.7 7.6
95% CI 7.4–7.9 6.7–7.2 n.a 7.4–8.2 8.0–9.0 9.0–10.9 5.8–7.7 7.4–10.2 7.4–7.7
2000 7.6 6.2 9.4 6.5 7.2 10.6 6.8 12.9 7.5
95% CI 7.4–7.8 5.9–6.4 9.0–9.7 6.1–6.9 6.8–7.7 9.7–11.5 5.8–7.6 11.2–14.7 7.4–7.6
• In 2000, the age-standardised rate of high-grade abnormalities varied considerably among
states and territories. The lowest rate was observed in Victoria (6.2 per 1,000 women) and
the highest rate was in the Northern Territory (12.9 per 1,000 women).
• Except in Tasmania, the Australian Capital Territory and the Northern Territory, in all
jurisdictions the age-standardised rate of high-grade abnormalities declined between 1999
and 2000. In Victoria, Western Australia, and South Australia the decreases in the rates of
high-grade abnormalities were statistically significant.
• In the Northern Territory and Tasmania, the rates increased between 1999 and 2000; of
these, only the increase in the Northern Territory is statistically significant.
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Incidence
A major objective of the National Cervical Screening Program is to minimise the incidence of
cervical cancer by detecting treatable pre-cancerous lesions before their progression to cancer.
However, where these pre-cancerous lesions cannot be detected, diagnosis of cancer at its
earliest stage, the micro-invasive stage, is the most desirable alternative. The next two
indicators measure the incidence rates of micro-invasive and all cervical cancers in the
community.
In 1994 the International Federation of Gynaecology and Obstetrics endorsed the following
definition of micro-invasive carcinoma of the cervix:
Stage 1a1. Measured invasion of stroma no greater than 3 mm in depth and no wider than
7 mm.
Stage 1a2. Measured invasion of stroma greater than 3 mm and no greater than 5 mm in depth
and no wider than 7 mm. The depth of invasion should not be more than
5 mm taken from the base of the epithelium, either surface or glandular, from which
it originates. Vascular space involvement, either venous or lymphatic, should not
alter the staging (Ostor & Mulvany 1996).
Micro-invasive squamous cell carcinoma makes up the largest share of the micro-invasive
cancer which is reported in Indicator 5. There are also other forms of micro-invasive cancers
such as adenocarcinoma and adeno-squamous cell carcinoma for which data are not available
to include in this indicator.
In interpreting cervical cancer incidence statistics, it should be noted that cervical screening has
been available on an ad hoc basis since the 1960s, but it is only since the late 1980s and early
1990s that there has been an organised national approach to screening at a population level.
The introduction of cervical screening programs may result in the paradox whereby in the
short term the number of new cases of micro-invasive cancer increases because cancers are
found earlier than they would have been without screening, with the rate of more advanced
cancers decreasing in the longer term.
For this report the most recent national data available on incidence data are for 1999, in contrast
to screening data which are available for 2000. This time lag in availability of incidence data is
expected to reduce over the next 2 years.
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Indicator 5: Incidence of micro-invasive cervical
cancer
Incidence rates of micro-invasive squamous cell carcinoma per 100,000 estimated resident
female population in a 12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39,
40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group
(20–69 years—age-standardised).
The graphs and tables below refer to the data for the target age group only. For detailed data
refer to Table 11 (page 53).
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 8: Age-standardised incidence rates for micro-invasive squamous cell cancer, women aged
20–69 years, Australia, 1988–1999
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
(Rate per 100,000 women)
AS rate 1.7 1.8 2.7 2.9 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5
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• The age-standardised incidence rate of micro-invasive cervical cancer was 1.4 per 100,000
women for all women in 1999, and 1.5 per 100,000 for the target age group 20–69 years
(Table 11, page 53).
• In 1999 there were 95 new cases of micro-invasive cervical cancer among women of all ages,
and for the target age group 20–69 years there were 92 new cases (Table 10, page 52).
• The age-standardised incidence rates for micro-invasive squamous cell carcinoma of the
cervix have fluctuated during the period 1988–1999. Note that the number of cases of micro-
invasive cancer is very low and the rates are therefore unstable (Tables 10 and 11, pages 52
and 53).
Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 9: Age-specific incidence rates of micro-invasive squamous cell cancer, women aged
20–69 years, Australia, 1998 and 1999
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69
1998 0.3 2.3 2.5 3.4 3.1 2.3 2.3 0.7 1.3 0.6
1999 0.3 1.9 2.0 2.6 2.1 1.0 1.2 1.8 0.5 0.9
• In both 1998 and 1999, women in the age group 35–39 years had the highest incidence rate
of micro-invasive squamous cell cancer. In 1999, there were 20 cases of micro-invasive
squamous cell cervical cancer in women aged 35–39 years. It should be noted that the rates
for age groups 45–49 and over in 1999 are based on small numbers of cases (less than 10
cases in each 5-year age group) (Tables 10 and 11, pages 52 and 53).
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Indicator 6: Incidence of invasive squamous,
adenocarcinoma, adeno-squamous and other cervical
cancer
Incidence rates of squamous, adenocarcinoma, adeno-squamous and other cervical cancer
per 100,000 estimated resident female population in a 12-month period, by 5-year age groups
(20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+)
and for the target age group (20–69 years—age-standardised).
For detailed data refer to Table 13 (page 55).
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 10: Age-standardised incidence rates of cervical cancer, Australia, 1988–1999
Age 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
(Rate per 100,000 women)
All ages 12.9 12.6 12.4 12.3 11.3 11.0 12.1 10.0 9.5 8.0 8.4 7.7
20–69 years 17.7 17.4 17.0 16.6 15.3 15.1 16.3 13.4 12.8 10.8 11.2 10.5
• In 1999, the incidence rate of all cervical cancers declined to 7.7 per 100,000 women for all
women in Australia, and 10.5 per 100,000 women in the target group (Table 13, page 55).
• In 1999, cervical cancer was the 10th most frequently diagnosed new cancer in women.
There were 787 new cases of cervical cancer diagnosed in Australia in 1999, and of these 646
were women in the target age group 20–69 years (Table 12, page 54).
• Between 1988 and 1999 the age-standardised incidence rate for cervical cancer for women of
all ages declined by 40.3%, and in the target age group by 40.7% (Table 13, page 55).
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Refer to Table 13 (page 55).
Note: Rates are expressed per 100,000 women.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 11: Age-specific incidence rates of cervical cancer, Australia, 1998 and 1999
Age group
Year 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 20–69
(Rate per 100,000 women)
1998 1.5 6.5 11.9 13.5 14.3 16.6 11.3 12.2 14.7 16.0 9.1
1999 1.1 7.5 10.3 13.1 14.5 11.4 10.8 10.5 16.3 15.6 8.2
• The age-specific rate of cervical cancer incidence rises rapidly in women from age 20–24
through to age 40–44 years; in 1999 the age-specific rate for women aged 40–44 years was
14.5 per 100,000 women. From that age, the rate declines to 10.5 at age group 55–59, and
then rises again.
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Refer to Tables 14b and 15b (pp. 57 and 59).
Notes
1. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
2. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 12: Age-standardised cervical cancer incidence rates, women aged 20–69 years, states and
territories, 1995–1998 and 1996–1999
NSW Vic Qld WA SA Tas ACT NT Australia
1995–1998 12.2 11.5 13.3 12.4 8.4 15.5 9.8 21.9 12.0
95% CI 11.4–13.0 10.6–12.4 12.2–14.4 10.8–13.9 7.1–9.6 12.2–18.9 6.6–13.0 15.2–28.6 11.6–12.5
1996–1999 11.4 10.3 13.5 10.6 9.1 14.1 9.0 18.7 11.3
95% CI 10.7–12.2 9.5–11.1 12.4–14.5 9.2–11.9 7.7–10.4 11.0–17.1 6.1–12.0 13.0–24.4 10.9–11.7
• There were considerable differences in the incidence of cervical cancer among states and
territories for women aged 20–69 years. In the period 1996–1999, the Australian Capital
Territory had the lowest incidence at 9.0 per 100,000 women while the Northern Territory
had the highest rate of cervical cancer incidence of 18.7 per 100,000 women. Both
Queensland (13.5) and the Northern Territory (18.7) were significantly above the national
average (11.3) while South Australia (9.1) was significantly below.
• Between the two periods 1995–1998 and 1996–1999 the incidence rate declined in all states
and territories except in Queensland and South Australia. However, the decline is not
statistically significant (Tables 14b and 15b, pages 57 and 59).
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Refer to Table 16b (page 60).
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 13: Age-standardised incidence rates of cervical cancer by histological type, women
aged 20–69 years, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 12.9 13.2 12.1 12.0 11.1 10.7 11.2 9.6 9.1 7.7 8.1 7.7
Adenocarcinoma 3.1 2.2 2.8 2.7 2.6 2.5 3.4 2.6 2.6 2.2 2.4 2.1
Adeno-squamous 0.8 0.9 0.9 0.8 0.9 0.9 0.7 0.6 0.7 0.5 0.5 0.4
Other 0.9 1.0 1.2 1.1 0.7 1.1 1.1 0.7 0.7 0.6 0.5 0.5
• In 1999, squamous cell carcinomas of the cervix accounted for approximately 71.8% of all
new cases of cervical cancer in women aged 20–69 years, adenocarcinomas 19.5%, adeno-
squamous 3.6% and a range of other mixed and unknown histologies comprised the
remaining 5.1% (Table 16a, page 60).
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Indicator 8: Incidence by location
Incidence rates of cervical cancer per 100,000 estimated resident female population in a
4-year period, by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age (20–69
years—age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Table 19 (page 63).
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data. These years were selected to be comparable
with the mortality by location indicator presented later in this report.
2. Rates are expressed per 100,000 women and age standardised to the Australian 1991 population.
3. Bars on graphs represent 95% confidence intervals.
Source: National Cancer Statistics Clearing House (AIHW).
Figure 14: Age-standardised incidence rates of cervical cancer, by location, women aged 20–69 years,
Australia, 1995–1998 and 1996–1999
Metropolitan Rural Remote
1995–1998 1996–1999 1995–1998 1996–1999 1995–1998 1996–1999
AS rate 12.1 11.3 11.7 11.3 15.2 14.5
95% CI 11.6–12.6 10.8–11.8 10.8–12.6 10.5–12.1 12.1–18.3 11.5–17.5
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• In the 4-year period 1996–1999 there were 2,432 new cases (72% of all new cases) of cervical
cancer in metropolitan locations, 840 new cases (25% of all new cases) in rural locations and
102 new cases (3% of all new cases) in remote locations (Table 18, page 62).
• In the period 1996–1999, the age-standardised cervical cancer incidence rate for women in
the target age group 20–69 years was higher in remote locations (14.5 per 100,000 women)
than in metropolitan and rural locations. This difference was not statistically significant.
During the same period, the corresponding rates of cervical cancer incidence in both
metropolitan and rural locations were 11.3 per 100,000 women (Table 19, page 63).
• The age-standardised incidence rate of cervical cancer in all locations for women aged
20–69 years declined between the periods 1995–1998 and 1996–1999. However, the decline
is not statistically significant.
Age-specific features
• Very few cervical cancers occur in women under the age of 20. The incidence rate of
cervical cancer increases with age.
• Between the periods 1995–1998 and 1996–1999 age-specific rates for the incidence of cervical
cancer declined in almost all ages in metropolitan and rural areas. However, the age pattern
of cervical cancer incidence in remote areas shows fluctuations between the same periods.
This may be due to the small numbers of cervical cancer occurring in these areas.
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Mortality
Cancer of the cervix is one of the few cancers for which there is an efficacious screening test for
detection of precursors of the disease at a pre-cancerous stage, and most deaths due to cervical
cancer are potentially avoidable (Marcus & Crane 1998). However, some deaths do occur and
the objective of the National Cervical Screening Program is to reduce this mortality rate.
These indicators measure the level of mortality from cervical cancer in the total female
population by age and other demographic characteristics. This indicator is important because
from it an assessment can be made of changes in mortality in different age groups and
particular target groups over time. However, it should be noted that changes in the mortality
rates may not be evident for a number of years following an improvement in the participation
rate. Therefore the effectiveness of this measure needs to be viewed in the longer rather than
the shorter term.
Data issues
• Two major changes that have occurred in the classification and processing of Australian
mortality data require some caution when interpreting mortality data over time. They are:
1. the introduction of the tenth revision of the International Classification of Diseases
(ICD-10) for classifying deaths registered from 1 January 1999; and
2. the introduction of the Automated Coding System (ACS) for processing deaths
registered from 1 January 1997.
• As a result of this there is now a break in the mortality data series. In order to make
mortality data coded using ICD-9 and ICD-10 comparable, the Australian Bureau of
Statistics (ABS) has derived comparability factors to adjust data based on ICD-9. These
comparability factors are derived from the movements in the underlying causes of death
coded in ICD-9 compared to ICD-10 (ABS 2000).
• For cervical cancer deaths, the comparability factor is 0.98, and the pre-1997 mortality data
presented in this report have been adjusted accordingly. The effect of this is that the pre-
1997 number of deaths appearing in this report are different from figures in previous
Cervical Screening in Australia reports.
• Prior to 1998, only South Australia, Western Australia and the Northern Territory had a
relatively high coverage of Indigenous status identification in the deaths data. In 1998
Queensland’s coverage of Indigenous deaths reached an acceptable level following the
introduction of a new Death Information Form in 1996–97 which included a question on
Indigenous status (ABS 1999). Therefore, in this report, cervical cancer deaths for
Indigenous Australians include data from Queensland (for 1998 to 2000), South Australia,
Western Australia and the Northern Territory.
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Indicator 7: Mortality
Death rates from cervical cancer per 100,000 estimated resident female population in a
12-month period by 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54,
55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69 years—
age-standardised).
Refer to Table 21 (p. 65).
Notes
1. Rates are expressed per 100,000 women.
2. Deaths were derived from place of usual residence and by year of registration
3. Rates for all ages are based on data for women aged 15 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
Source: AIHW Mortality Database.
Figure 15: Age-standardised death rates from cervical cancer, Australia, 1981–2000
’81 ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00
All ages 6.2 5.9 5.5 5.4 5.7 5.4 5.0 5.1 5.2 4.9 4.6 4.3 4.1 4.3 4.2 3.7 3.5 3.1 2.5 3.0
20–69 years 5.0 5.1 5.1 4.7 4.8 4.9 4.2 4.3 4.4 4.6 3.8 3.3 3.5 3.8 3.6 2.9 2.8 2.5 2.0 2.5
• Cervical cancer was the 15th most common cause of cancer deaths in Australian women in
2000, accounting for 267 deaths.
• The age-standardised death rate for women of all ages was 3.0 per 100,000 in 2000.
Mortality from cervical cancer, although fluctuating, has declined over time.
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Notes
1. Rates are expressed per 100,000 women.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
Figure 16: Age-specific cervical cancer death rates, by age group, Australia, 1987–1990 and 1997–2000
Age group
Period 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+
1987–1990 0.1 0.7 2.3 3.2 4.4 6.3 5.6 8.1 9.3 13.8 15.2 15.0 16.2 19.3
1997–2000 0.2 0.5 1.0 1.9 2.4 3.7 3.4 4.1 5.9 6.9 9.9 10.0 13.1 16.8
• The age-specific rates of cervical cancer mortality increased with rising age—very few
deaths occurred at younger ages while most deaths concentrated at older ages. In the
period 1997–2000, within the target age group, the age-specific mortality ranged from
0.2 deaths per 100,000 women in the age group 20–24 to 6.9 deaths per 100,000 women in
the age group 65–69.
• The age-specific mortality between the two reference periods declined in all age groups
except for the age group 20–24 years.
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Refer to Tables 23 and 25 (pp. 67 and 69).
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 17: Age-standardised cervical cancer death rates, women aged 20–69 years, states and
territories, 1993–1996 and 1997–2000
NSW VIC QLD WA SA Tas ACT NT Australia
Rate 1993–1996 3.5 3.0 3.5 4.4 2.3 5.7 3.2 11.8 3.4
95% CI 3.1–4.0 2.5–3.4 2.9–4.0 3.4–5.2 1.6–2.9 3.7–7.5 1.5–5.2 5.8–18.8 3.2–3.7
Rate 1997–2000 2.5 1.9 2.9 2.9 1.8 3.5 3.7 4.4 2.4
95% CI 2.1–2.9 1.5–2.2 2.3–3.3 2.2–3.6 1.3–2.4 2.1–5.1 1.8–6.0 1.6–7.6 2.2–2.6
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• There were 1,046 deaths from cervical cancer in all states and territories in 1997–2000.
• The age-standardised mortality rates varied from 4.4 per 100,000 women in the Northern
Territory to 1.8 per 100,000 women in South Australia. Although the Northern Territory
mortality rate declined considerably between the two periods, the rates are based on a very
small number of deaths and are therefore subject to great variability.
• In all jurisdictions except the Australian Capital Territory the death rate declined between
the two periods. Only the declines in New South Wales and Victorian rates, however, are
statistically significant.
• The mortality rate in the Australian Capital Territory increased between the two periods;
this increase is not statistically significant.
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Indicator 9: Mortality by location
Death rates from cervical cancer per 100,000 estimated resident female population in a
4-year period, by location and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69
years—age-standardised).
The graph and table below refer to the data for the target age group only. For additional data
refer to Tables 26 and 27, pages 70 and 71)
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 18: Age-standardised cervical cancer death rates, by location, women aged 20–69 years,
1993–1996 and 1997–2000
Metropolitan Rural Remote
1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
Rate 3.2 2.4 3.6 2.4 7.4 3.7
95% CI 3.0–3.5 2.2–2.6 3.2–4.1 2.1–2.8 5.0–9.9 2.2–5.4
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• During the 4-year period 1997–2000 there were 735 deaths (70% of all cervical deaths in that
period) in metropolitan areas, 276 deaths (26% of all cervical deaths) in rural areas and 35
deaths (4% of all cervical deaths) in remote areas (Table 26, page 70).
• The age-standardised death rate for women in the target age group 20–69 years was highest
in remote locations. The difference was statistically significant from other locations in the
period 1993–1996, but during the period 1997–2000, the difference was not statistically
significant. The high rate of mortality in remote locations may reflect the relatively high
proportion of Indigenous people in remote areas, and the high death rates among
Indigenous women. Both metropolitan and rural locations had similar rates of mortality
from cervical cancer.
• In all three regions the age-standardised mortality rates declined between the periods 1993–
1996 and 1997–2000; however, only the declines in metropolitan and rural areas were
statistically significant. The largest overall mortality reduction was in remote areas (a
mortality reduction of 50% between 1993–1996 and 1997–2000), but these rates are based on
small numbers and therefore the decline is not statistically significant. Between the same
two periods, in metropolitan areas, there was a 25% decline in cervical cancer mortality and
in rural areas, it was 33%.
Age-specific features
• In the target age group of 20–69 years, age-specific mortality from cervical cancer increases
with age. However, it is higher still among women in their 70s and 80s.
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Indicator 10: Indigenous mortality
Death rates from cervical cancer per 100,000 estimated resident female population in a
4-year period, by Indigenous status and 5-year age groups (20–24, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group (20–69
years—age-standardised).
The graph and table below refer to the data for the target age group only. For detailed data
refer to Tables 28 and 29 (pages 72 and 73).
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population.
4. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
5. Bars on graphs represent 95% confidence intervals.
Source: AIHW Mortality Database.
Figure 19: Age-standardised cervical cancer mortality rates, by Indigenous status, women aged
20–69 years, 1995–1998, 1996–1999 and 1997–2000
Indigenous Non-Indigenous
1995–1998 1996–1999 1997–2000 1995–1998 1996–1999 1997–2000
AS rate 17.5 10.6 11.3 2.3 1.9 2.1
95% CI 8.8–26.5 5.2–17.1 6.2–17.1 1.9–2.7 1.6–2.3 1.7–2.4
Note: Indigenous and non-Indigenous deaths from Queensland for 1998, 1999 and 2000 are included in the above table.
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• Due to the difficulties of Indigenous identification in health data collections, only
Indigenous mortality data from Queensland (from 1998), Western Australia, South
Australia and the Northern Territory are considered to be of publishable standard.
Therefore, all cervical cancer mortality data for both Indigenous women and non-
Indigenous women used in this analysis are confined to these jurisdictions.
• There were 22 deaths, an age-standardised rate of 11.3 per 100,000 women, attributable to
cervical cancer among Indigenous women in the target age group in 1997–2000 period. This
is over 5 times the mortality rate for non-Indigenous women in the same age range (2.1 per
100,000 women) (Tables 28 and 29, pages 72 and 73).
• The Indigenous cervical cancer mortality rate among women in the target age group
declined over time from 17.5 in 1995–1998 to 11.3 deaths per 100,000 women in
1997–2000. The Queensland data only cover part of this period, so their inclusion may effect
the comparison. When Queensland data were excluded from the analysis, the Indigenous
mortality rate from cervical cancer still declined from 22 in 1995–1998 to 15.1 per 100,000
women in 1997–2001. However, the death rates for Indigenous women are based on
relatively small numbers of cases and may be subject to large variability. This is reflected in
the wide confidence intervals associated with the mortality rates. Despite the relatively
large size of the apparent decline in the rate, it is still within the range of variation that
would be expected due to chance, that is, it is not statistically significant (Table 29, page 73).
• Mortality from cervical cancer among non-Indigenous women fluctuated over time.
Age-specific features
• The numbers of deaths among Indigenous women in Queensland, Western Australia, South
Australia and the Northern Territory are either very small or none in many age groups and
care is needed in interpreting the rates.
• Mortality rates generally increased with increasing age in both Indigenous and non-
Indigenous women.
• Compared with non-Indigenous women, Indigenous women experienced high rates of
mortality in every age group.
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Tables
Indicator 1: Participation rate for cervical screening
Table 1a: Number of women participating in the National Cervical Screening Program, by age, states
and territories, 1998–1999
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Total
20–24 105,105 89,660 36,858 27,282 9,466 6,803 4,700 279,874
25–29 152,831 128,002 47,821 36,257 11,298 8,589 6,208 391,006
30–34 154,747 129,131 48,370 37,393 11,482 8,293 5,586 395,002
35–39 158,287 129,303 49,374 39,258 12,479 8,350 4,963 402,014
40–44 135,791 112,158 43,327 35,207 10,685 7,563 4,050 348,781
45–49 114,246 96,199 35,585 30,489 9,030 7,019 3,321 295,889
50–54 91,705 77,518 26,608 24,842 7,222 5,785 2,217 235,897
55–59 61,286 52,870 17,411 16,762 4,845 3,404 1,273 157,851
60–64 45,955 41,426 13,272 13,327 3,689 2,177 641 120,487
65–69 32,950 32,337 9,512 10,243 2,753 1,413 355 89,563
70–74 14,341 12,107 3,656 7,043 842 583 147 38,719
75–79 5,440 4,559 1,311 n.a. 334 198 72 11,914
80+ 2,051 2,055 431 n.a. 134 67 23 4,761
Not stated 5,485 n.a. n.a. 31 7 15 28 5,566
All ages 1,080,220 907,325 333,536 278,134 84,266 60,259 33,584 2,777,324
Ages 20–69
years 1,052,903 888,604 328,138 271,060 82,949 59,396 33,314 2,716,364
(a) The WA and ACT registers only register women with a valid WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table, they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate Registers and inclusion of women
resident overseas.
2. The Queensland Health Pap Smear Register began operations in February 1999. Hence no data are available for 1998–1999.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 1b: Proportion of women participating in the National Cervical Screening Program, by age,
states and territories, 1998–1999
Age group NSW Vic WA(a) SA(b) Tas ACT(a) NT Total
(Per cent)
20–24 48.1 53.6 54.7 55.9 63.7 51.9 59.7 52.0
25–29 62.3 69.2 67.6 68.9 70.1 65.4 65.8 66.0
30–34 66.6 72.9 71.2 71.5 71.6 69.3 66.9 69.7
35–39 67.9 75.5 72.3 72.9 72.4 71.5 67.7 71.4
40–44 67.2 74.9 71.2 74.0 70.0 71.8 68.0 70.9
45–49 66.1 74.7 68.8 72.2 68.8 73.1 71.1 69.9
50–54 68.5 78.0 70.7 75.4 71.1 82.4 70.6 72.8
55–59 59.2 69.6 61.9 66.9 60.7 74.3 67.0 63.9
60–64 52.0 63.6 57.5 61.2 54.1 66.1 53.8 57.4
65–69 39.1 52.2 45.7 48.5 42.3 51.7 44.9 45.2
All ages
Crude rate 56.9 64.1 61.9 62.2 60.9 64.2 64.9 60.6
AS rate 56.2 63.8 60.4 62.8 60.9 62.6 60.4 60.0
95% CI 56.1–56.3 63.6–63.9 60.2–60.6 62.5–63.0 60.5–61.4 62.1–63.1 59.7–61.2 59.9–60.0
Ages 20–69 years
Crude rate 61.4 69.3 66.1 68.1 66.8 67.8 65.8 65.4
AS rate 60.8 68.9 65.4 67.6 66.3 67.6 64.5 64.8
95% CI 60.7–60.9 68.8–69.0 65.1–65.6 67.3–67.8 65.8–66.7 67.0–68.1 63.7–65.3 64.8–64.9
(a) The WA and ACT registers only register women with a valid WA and ACT address respectively.
(b) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. The Queensland Health Pap Smear Register began operations in February 1999. Hence no data are available for 1998–1999.
3. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 2a: Number of women participating in the National Cervical Screening Program, by age, states
and territories, 1999–2000
Age group NSW Vic Qld WA(a) SA(b) Tas ACT(a) NT Australia
20–24 99,812 83,943 64,583 34,401 25,727 8,939 6,354 4,587 328,346
25–29 147,289 120,835 82,879 44,631 33,896 10,398 8,083 6,067 454,078
30–34 151,934 125,001 81,147 46,230 36,101 11,047 8,072 5,782 465,314
35–39 156,192 124,293 83,093 47,573 38,032 11,999 7,964 4,941 474,087
40–44 137,205 110,095 73,124 42,825 35,019 10,864 7,369 4,170 420,671
45–49 115,982 94,509 61,746 35,698 30,326 9,101 6,706 3,490 357,558
50–54 95,632 78,785 50,876 27,795 25,564 7,582 5,848 2,491 294,573
55–59 64,864 53,943 33,397 17,857 17,313 5,123 3,485 1,444 197,426
60–64 48,312 41,339 23,470 13,451 13,827 3,822 2,243 719 147,183
65–69 34,003 30,654 16,317 9,346 10,135 2,849 1,388 401 105,093
70–74 14,487 11,283 7,955 3,583 6,517 788 491 147 45,251
75–79 5,487 4,233 3,228 1,230 n.a. 321 168 79 14,746
80+ 2,113 1,946 1,423 542 n.a. 140 58 20 6,242
Not stated 3,720 27 408 0 24 4 15 21 4,219
All ages 1,077,032 880,886 583,646 325,162 272,481 82,977 58,244 34,359 3,314,787
Ages 20–69
years 1,051,225 863,397 570,632 319,807 265,940 81,724 57,512 34,092 3,244,329
(a) The WA and ACT registers only register women with a valid WA or ACT address respectively.
(b) South Australia has grouped women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Table 2b: Proportion of women participating in the National Cervical Screening Program, by age,
states and territories, 1999–2000
Age group NSW Vic Qld WA(a) SA(b) Tas ACT(c) NT Australia
(Per cent)
20–24 45.6 50.0 51.7 50.6 53.5 61.3 48.8 58.8 49.5
25–29 59.6 65.5 61.2 62.9 65.8 66.3 62.1 64.9 62.4
30–34 65.3 69.9 64.0 67.9 69.9 70.1 67.7 67.6 67.0
35–39 67.2 72.3 64.8 69.5 71.5 71.2 69.2 66.6 68.7
40–44 67.0 72.5 64.8 69.5 72.6 70.7 69.7 69.7 68.8
45–49 66.1 72.1 63.2 67.3 71.3 68.4 70.2 72.4 67.8
50–54 69.3 76.4 65.9 70.3 75.1 72.2 79.9 75.2 71.3
55–59 60.2 68.3 57.1 60.7 66.3 62.0 71.7 70.0 62.5
60–64 53.7 62.2 51.0 56.4 62.3 54.6 65.3 58.6 56.5
65–69 40.8 49.7 39.9 44.5 48.6 43.9 49.9 48.3 44.2
All ages
Crude rate 55.2 60.4 55.4 58.5 59.5 58.9 61.4 65.3 57.5
AS rate 55.0 60.4 54.5 57.4 60.4 59.4 59.5 60.7 57.2
95% CI 54.9–55.1 60.3–60.6 54.4–54.7 57.2–57.6 60.2–60.6 59.0–59.8 58.9–60.0 60.0–61.4 57.1–57.2
Ages 20–69 years
Crude rate 60.7 66.6 60.2 63.5 66.7 66.0 65.3 66.4 63.1
AS rate 60.2 66.2 59.5 62.8 66.2 65.5 65.1 65.6 62.6
95% CI 60.1–60.3 66.1–66.3 59.3–59.6 62.6–63.1 66.0–66.5 65.0–65.9 64.6–65.7 64.9–66.4 62.5–62.6
(a) The WA and ACT registers only register women with a valid WA and ACT address respectively.
(b) South Australia has grouped all women aged 70 years or more, and for the purposes of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. Queensland data for the 1999–2000 period refer to the 2-year period from March 1999 to February 2001.
3. Rates are standardised to the 1991 Australian total population.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Indicator 2: Early re-screening
Table 3: Number of women with repeat screenings in the 21 months following a negative Pap smear
in February 1999, states and territories, and Australia, 1999–2000
No. of tests NSW Vic Qld WA(a) SA Tas ACT(a) NT Australia
0 36,482 33,041 23,870 10,568 9,438 2,624 2,147 1,386 119,556
1 15,212 14,126 8,341 4,601 3,411 1,012 723 490 47,916
2 1,902 2,126 1,202 547 478 138 125 73 6,591
3 317 504 244 96 97 28 16 8 1,310
4 45 117 62 16 23 4 2 0 269
5 or more 6 55 10 3 5 1 0 1 81
(a) The WA and ACT registries only register women with a valid WA and ACT address respectively.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate Registers and inclusion of women resident
overseas.
2. The follow-up period for Queensland data is from March 1999 to December 2000.
Source: State and territory Cervical Cytology Registry data.
Table 4: Percentage of women with repeat screenings in the 21 months following a negative smear in
February 1999, states and territories, and Australia, 1999–2000
No. of tests NSW Vic Qld WA(a) SA Tas ACT(a) NT Australia
0 67.5 66.1 70.8 66.8 70.2 68.9 71.3 70.8 68.0
1 28.3 28.3 24.7 29.1 25.4 26.6 24.0 25.0 27.3
2 3.5 4.3 3.6 3.5 3.6 3.6 4.1 3.7 3.8
3 0.6 1.0 0.7 0.6 0.7 0.7 0.5 0.4 0.7
4 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.0 0.2
5 or more 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0
(a) The WA and ACT registries only register women with a valid WA and ACT address respectively.
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas.
Source: State and territory Cervical Cytology Registry data.
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Indicator 3: Low-grade abnormality detection
Table 5a: Number of low- and high-grade abnormalities on histology for women aged 20–69 years,
states and territories, 1999
Abnormalities NSW Vic WA SA Tas ACT NT Total
Low-grade 6,207 4197 2563 1767 640 221 158 15,753
High-grade 4,523 3546 1509 1237 470 178 179 11,642
Ratio 1.37 1.18 1.70 1.43 1.36 1.24 0.88 1.35
As a percentage of all screens in 1999
Low-grade 1.0 0.8 1.3 1.2 1.4 1.8 0.9 1.0
High-grade 0.8 0.7 0.8 0.8 1.0 1.4 1.0 0.8
Notes
1. The Queensland Health Pap Smear Register began operations in February 1999; therefore no data are available for 1999.
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
Table 5b: Number of low- and high-grade abnormalities on histology for women aged 20–69 years,
states and territories, 2000
Abnormalities NSW Vic Qld WA SA Tas ACT NT Australia
Low-grade 6,381 3,701 5,016 2,075 1,541 678 273 320 19,985
High-grade 4,493 2,986 3,105 1,240 1,045 478 220 284 13,851
Ratio 1.42 1.24 1.62 1.67 1.47 1.42 1.24 1.13 1.44
As a percentage of all screens in 2000
Low-grade 1.1 0.7 1.6 1.1 1.0 1.5 0.5 1.6 1.1
High-grade 0.7 0.6 1.0 0.6 0.7 1.0 0.4 1.4 0.7
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty
in identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women
resident overseas.
Source: State and territory Cervical Cytology Registry data.
45
Indicator 4: High-grade abnormality detection
Table 6a: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, by
age, states and territories, 1999
Age group NSW Vic WA SA(a) Tas ACT NT Total
20–24 18.3 15.9 15.5 16.8 23.1 8.5 13.4 16.8
25–29 14.8 14.1 17.4 15.4 21.0 10.1 15.8 15.0
30–34 9.9 9.2 10.6 11.8 12.1 10.1 11.1 10.0
35–39 6.7 6.2 6.7 7.0 8.4 8.3 9.6 6.7
40–44 4.3 3.8 4.4 6.5 5.8 5.5 4.0 4.4
45–49 3.0 2.7 3.1 5.0 4.6 4.4 4.8 3.2
50–54 2.2 1.4 1.5 2.9 3.0 1.5 3.9 2.0
55–59 1.4 1.5 1.6 2.6 1.4 3.1 7.9 1.7
60–64 1.3 1.7 1.6 1.8 1.9 3.4 0.0 1.6
65–69 2.2 1.3 2.3 2.4 1.3 6.8 9.3 2.0
70–74 1.7 2.4 0.9 6.8 4.4 10.9 12.8 2.9
75–79 4.5 1.5 5.7 n.a. 0.0 48.1 0.0 4.1
80–84 2.4 2.5 3.8 n.a. 20.4 0.0 0.0 3.0
85+ 0.0 2.9 44.4 n.a. 0.0 0.0 0.0 4.4
All ages 7.4 6.8 7.8 8.3 9.9 7.0 9.7 7.5
Ages 20–69
years 7.6 6.9 7.9 8.4 10.0 6.8 9.7 7.5
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. No data were available for Queensland for this period.
Source: State and territory Cervical Cytology Registry data.
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Table 6b: Rate of histologically confirmed high-grade abnormalities per 1,000 women screened, by
age, states and territories, 2000
Age group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 17.0 13.8 19.0 13.8 13.8 27.0 13.8 24.0 16.3
25–29 15.4 13.1 19.7 14.8 13.8 18.1 9.4 23.7 15.5
30–34 10.3 8.6 12.8 9.1 10.9 12.1 12.1 15.6 10.3
35–39 6.2 5.3 8.6 5.6 6.1 10.9 5.4 12.3 6.5
40–44 5.0 3.4 5.5 3.2 4.9 7.0 3.1 11.5 4.5
45–49 2.8 2.3 4.1 2.2 3.4 4.4 4.8 6.3 3.0
50–54 1.9 1.2 2.6 1.3 2.3 3.4 3.6 1.4 1.9
55–59 1.3 1.0 3.0 1.0 1.8 1.7 2.5 3.6 1.5
60–64 1.4 1.1 1.5 1.7 2.4 1.4 1.6 4.7 1.5
65–69 2.2 1.1 1.6 1.0 2.0 2.6 2.6 9.5 1.7
70–74 3.0 2.0 2.4 1.3 8.6 2.3 0.0 12.7 3.2
75–79 3.7 2.1 6.0 1.1 n.a. 0.0 50.0 0.0 3.8
80–84 4.8 2.5 9.5 0.0 n.a. 0.0 0.0 0.0 4.3
85+ 6.5 0.0 0.0 8.4 n.a. 0.0 0.0 0.0 3.1
All ages 7.3 5.9 9.5 6.3 7.0 10.2 6.9 14.3 7.3
Ages 20–69
years 7.4 6.0 9.6 6.4 7.0 10.4 6.8 14.3 7.4
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
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Table 7a: Number of histologically confirmed high-grade abnormalities, by age, states and territories,
1999
Age group NSW Vic WA SA(a) Tas ACT NT Total
20–24 1,031 787 316 247 118 31 35 2,565
25–29 1,252 1,031 466 300 131 49 54 3,283
30–34 859 690 290 240 79 46 34 2,238
35–39 599 461 188 150 59 38 25 1,520
40–44 332 249 114 125 36 23 9 888
45–49 201 152 67 84 24 17 9 554
50–54 122 64 25 41 13 5 5 275
55–59 51 48 17 24 4 6 6 156
60–64 35 40 13 13 4 4 0 109
65–69 41 22 13 13 2 5 2 98
70–74 14 16 2 23 2 3 1 61
75–79 14 4 5 0 0 5 0 28
80–84 2 2 1 0 1 0 0 6
85+ 0 1 2 0 0 0 0 3
Age not
stated 5 0 0 0 0 0 0 5
All ages 4,558 3,569 1,519 1,260 473 232 180 11,789
Ages 20–69
years 4,523 3,546 1,509 1,237 470 224 179 11,686
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. No data were available for Queensland for this period.
Source: State and territory Cervical Cytology Registry data.
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Table 7b: Number of histologically confirmed high-grade abnormalities, by age, states and
territories, 2000
Age group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 924 632 665 266 196 131 46 62 2,922
25–29 1,284 880 904 379 260 105 42 83 3,937
30–34 898 619 593 249 224 75 56 53 2,767
35–39 559 373 400 158 131 73 24 36 1,754
40–44 399 217 231 84 97 44 13 28 1,113
45–49 192 128 146 50 58 23 18 13 628
50–54 107 58 75 23 33 15 12 2 325
55–59 49 31 57 11 17 5 5 3 178
60–64 40 28 20 14 18 3 2 2 127
65–69 41 20 14 6 11 4 2 2 100
70–74 24 13 10 3 31 1 0 1 83
75–79 11 5 10 1 0 0 4 0 31
80–84 4 2 5 0 0 0 0 0 11
85+ 2 0 0 1 0 0 0 0 3
Age not
stated 2 0 1 0 0 0 0 0 3
All ages 4,536 3,006 3,131 1,245 1,076 479 224 285 13,982
Ages 20–69
years 4,493 2,986 3,105 1,240 1,045 478 220 284 13,851
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
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Table 8a: Number of women screened, by age, states and territories, 1999
Age group NSW Vic WA SA(a) Tas ACT NT Total
20–24 56,207 49,642 20,430 14,682 5,112 3,647 2,617 152,337
25–29 84,768 72,923 26,751 19,534 6,247 4,856 3,420 218,499
30–34 87,185 74,662 27,357 20,319 6,536 4,573 3,068 223,700
35–39 89,864 74,680 28,256 21,299 7,065 4,557 2,616 228,337
40–44 77,916 65,350 25,624 19,272 6,199 4,184 2,225 200,770
45–49 66,105 56,250 21,453 16,760 5,225 3,875 1,860 171,528
50–54 54,472 46,336 16,802 13,938 4,302 3,299 1,289 140,438
55–59 36,266 31,374 10,801 9,400 2,854 1,922 757 93,374
60–64 27,057 23,708 8,133 7,351 2,113 1,164 361 69,887
65–69 18,896 17,423 5,611 5,476 1,582 738 215 49,941
70–74 8,061 6,696 2,276 3,361 451 276 78 21,199
75–79 3,103 2,600 872 n.a. 173 104 46 6,898
80–84 832 811 260 n.a. 49 19 7 1,978
85+ 263 344 45 n.a. 21 10 2 685
Age not
stated
2,406 0 0 11 5 8 11 2,441
All ages 613,401 522,799 194,671 151,403 47,934 33,232 18,572 1,582,012
Ages 20–69
years 598,736 512,348 191,218 148,031 47,235 32,815 18,428 1,548,811
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Notes
1. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
2. No data were available for Queensland for this period.
Source: State and territory Cervical Cytology Registry data.
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Table 8b: Number of women screened, by age, states and territories, 2000
Age
group NSW Vic Qld WA SA(a) Tas ACT NT Australia
20–24 54,311 45,637 35,011 19,340 14,251 4,849 3,332 2,581 179,312
25–29 83,176 67,289 45,787 25,623 18,861 5,813 4,489 3,496 254,534
30–34 87,608 71,913 46,487 27,275 20,521 6,217 4,611 3,399 268,031
35–39 89,792 70,492 46,677 28,213 21,478 6,679 4,474 2,935 270,740
40–44 79,978 64,332 42,141 26,282 19,986 6,288 4,180 2,440 245,627
45–49 67,717 55,487 35,455 22,617 17,160 5,216 3,779 2,056 209,487
50–54 56,503 47,826 29,398 17,830 14,521 4,348 3,316 1,445 175,187
55–59 38,304 32,441 19,203 11,521 9,678 2,972 2,001 823 116,943
60–64 27,659 24,586 13,156 8,448 7,654 2,165 1,290 425 85,383
65–69 19,011 17,734 8,744 5,856 5,372 1,546 774 211 59,248
70–74 8,019 6,600 4,195 2,358 3,594 435 268 79 25,548
75–79 2,964 2,391 1,659 905 0 168 80 37 8,204
80–84 842 798 529 300 0 39 19 8 2,535
85+ 306 321 187 119 0 29 5 3 970
Age not
stated 1,734 0 207 0 11 0 7 16 1,975
All
ages 617,924 507,847 328,836 196,687 153,087 46,764 32,625 19,954 1,903,724
Ages
20–69
years 604,059 497,737 322,059 193,005 149,482 46,093 32,246 19,811 1,864,492
(a) South Australia has grouped all women aged 70 years or more, and for the purpose of this table they appear in the 70–74 age group.
Note: These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: State and territory Cervical Cytology Registry data.
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Table 9a: Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged
20–69 years, states and territories, 1999
NSW Vic WA SA Tas ACT NT Total
All ages
AS rate 7.1 6.4 7.8 7.9 9.5 6.5 8.4 7.1
95% CI 6.9–7.3 6.2–6.7 7.0–8.8 7.4–8.3 8.4–10.7 5.5–7.5 6.8–10.2 7.0–7.3
Target age 20–69
AS rate 7.7 6.9 7.7 8.5 9.9 6.8 8.7 7.6
95% CI 7.4–7.9 6.7–7.2 7.4–8.2 8.0–9.0 9.0–10.9 5.8–7.7 7.4–10.2 7.4–7.7
Notes
1. No data were available for Queensland for this period.
2. Standardised to the 1991 Australian total population.
3. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
Table 9b: Age-standardised high-grade abnormality rate on histology per 1,000 women screened aged
20–69 years, states and territories, 2000
NSW Vic Qld WA SA Tas ACT NT Australia
All ages
AS rate 7.1 5.7 8.8 5.8 6.8 9.6 7.6 12.1 7.1
95% CI 6.9–7.4 5.5–6.0 8.5–9.2 5.5–6.1 6.4–7.2 8.7–10.5 6.0–9.7 10.4–14.0 7.0–7.2
Target age
20–69
AS rate 7.6 6.2 9.4 6.5 7.2 10.6 6.8 12.9 7.5
95% CI 7.4–7.8 5.9–6.4 9.0–9.7 6.1–6.9 6.8–7.7 9.7–11.5 5.8–7.6 11.2–14.7 7.4–7.6
Notes
1. Rates are standardised to the 1991 Australian total population.
2. These numbers may be over-estimated because of double counting of some women between some states. This may be the result of difficulty in
identifying state of residence for women in border areas, tests inadvertently transferred to interstate registers and inclusion of women resident
overseas.
Source: AIHW analysis of state and territory Cervical Cytology Registry data.
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Indicator 5: Incidence of micro-invasive cervical cancer
Table 10: New cases of micro-invasive cervical cancer, by age, Australia, 1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 1 0 0 0 0 1 0 0 0
20–24 4 1 4 0 5 1 7 1 6 3 2 2
25–29 13 13 14 14 14 9 17 16 17 10 17 14
30–34 20 28 32 31 32 32 36 42 18 27 18 14
35–39 13 10 24 40 25 26 29 29 35 21 26 20
40–44 12 17 25 30 24 17 24 30 23 21 22 15
45–49 9 6 18 9 13 14 26 23 12 11 15 7
50–54 6 4 5 11 12 17 9 12 11 8 13 7
55–59 5 5 8 7 11 4 5 9 7 8 3 8
60–64 2 7 8 7 8 7 10 11 6 5 5 2
65–69 2 2 6 7 9 10 6 7 10 2 2 3
70–74 0 0 2 4 2 3 6 5 3 4 3 2
75–79 1 1 3 3 2 1 3 5 2 2 2 1
80–84 0 1 0 2 0 0 0 1 1 0 2 0
85+ 0 0 0 0 0 1 2 1 1 0 0 0
All ages 87 95 149 166 157 142 180 192 153 122 130 95
Ages 20–69
years 86 93 144 156 153 137 169 180 145 116 123 92
Source:  National Cancer Statistics Clearing House (AIHW).
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Table 11: Age-specific and age-standardised rates of micro-invasive cervical cancer, by age, Australia,
1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0
20–24 0.6 0.2 0.6 0.0 0.7 0.1 1.0 0.1 0.9 0.4 0.3 0.3
25–29 1.9 1.8 2.0 2.0 2.0 1.3 2.5 2.3 2.4 1.4 2.3 1.9
30–34 3.0 4.1 4.6 4.4 4.4 4.4 4.9 5.7 2.5 3.8 2.5 2.0
35–39 2.0 1.5 3.7 6.0 3.7 3.8 4.2 4.1 4.8 2.8 3.4 2.6
40–44 2.1 2.9 4.0 4.7 3.7 2.6 3.7 4.5 3.4 3.0 3.1 2.1
45–49 2.1 1.3 3.8 1.8 2.4 2.4 4.4 3.7 1.9 1.7 2.3 1.0
50–54 1.6 1.0 1.2 2.7 2.8 3.9 2.0 2.5 2.2 1.5 2.3 1.2
55–59 1.4 1.4 2.2 2.0 3.0 1.1 1.3 2.3 1.7 1.9 0.7 1.8
60–64 0.5 1.9 2.2 1.9 2.2 1.9 2.8 3.1 1.7 1.4 1.3 0.5
65–69 0.6 0.6 1.7 2.0 2.5 2.8 1.7 2.0 2.8 0.6 0.6 0.9
70–74 0.0 0.0 0.7 1.4 0.7 1.0 1.9 1.5 0.9 1.2 0.9 0.6
75–79 0.5 0.5 1.4 1.3 0.9 0.4 1.3 2.1 0.8 0.8 0.7 0.4
80–84 0.0 0.7 0.0 1.4 0.0 0.0 0.0 0.6 0.6 0.0 1.1 0.0
85+ 0.0 0.0 0.0 0.0 0.0 0.8 1.6 0.7 0.7 0.0 0.0 0.0
All ages
Crude rate 1.5 1.6 2.5 2.7 2.5 2.2 2.8 2.9 2.3 1.8 1.9 1.4
AS rate (A) 1.5 1.6 2.5 2.7 2.5 2.3 2.8 3.0 2.3 1.8 1.9 1.4
95% CI 1.2–1.9 1.2–1.9 2.1–2.9 2.3–3.1 2.1–2.9 1.9–2.6 2.4–3.2 2.5–3.3 1.9–2.7 1.5–2.1 1.5–2.1 1.1–1.7
AS rate (W) 1.6 1.6 2.5 2.6 2.5 2.2 2.8 2.9 2.3 1.8 1.9 1.4
95% CI 1.2–1.9 1.2–1.8 2–2.9 2.2–3 2.1–2.9 1.8–2.5 2.4–3.2 2.4–3.2 1.9–2.6 1.4–2.1 1.5–2.1 1.1–1.7
Age 20–69 years
Crude rate 1.7 1.8 2.7 2.9 2.8 2.5 3.0 3.2 2.5 2.0 2.1 1.5
AS rate (A) 1.7 1.8 2.7 2.9 2.8 2.5 3.0 3.1 2.5 2.0 2.0 1.5
95% CI 1.3–2.1 1.4–2.2 2.3–3.2 2.4–3.3 2.3–3.2 2.0–2.9 2.5–3.4 2.7–3.6 2.1–2.9 1.6–2.3 1.7–2.4 1.2–1.8
AS rate (W) 1.7 1.7 2.6 2.7 2.7 2.3 2.9 3.0 2.4 1.9 2.0 1.5
95% CI 1.3–2.0 1.4–2.0 2.2–3.0 2.3–3.1 2.3–3.1 1.9–2.7 2.5–3.3 2.6–3.4 2.0–2.8 1.5–2.2 1.6–2.3 1.2–1.8
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source:  National Cancer Statistics Clearing House (AIHW).
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Indicator 6: Incidence of invasive squamous, adenocarcinoma,
adeno-squamous and other cervical cancer
Table 12: New cases of cervical cancer, by age, Australia, 1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 1 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 1 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0
15–19 4 1 1 1 0 1 1 2 1 1 2 0
20–24 19 16 12 12 9 9 16 3 15 10 10 7
25–29 77 67 59 47 53 37 50 51 43 43 48 55
30–34 128 131 112 119 106 105 123 112 68 78 85 74
35–39 137 122 155 140 126 129 130 110 141 99 102 100
40–44 124 127 139 150 130 128 131 118 116 102 101 104
45–49 92 93 121 105 100 101 131 99 102 79 109 76
50–54 63 82 68 90 77 89 88 58 80 75 65 65
55–59 67 83 80 63 78 78 73 69 63 51 53 48
60–64 90 86 78 81 76 76 88 71 61 51 55 63
65–69 102 99 75 89 87 91 94 77 65 56 56 54
70–74 54 66 66 78 72 64 77 73 59 45 61 44
75–79 50 51 51 48 53 46 65 50 51 46 45 41
80–84 35 28 29 36 35 37 40 30 41 32 39 35
85+ 23 19 23 33 22 21 24 34 25 28 29 21
All ages 1,066 1,071 1,069 1,092 1,024 1,012 1,132 957 931 796 860 787
Ages 20–69 years 899 906 899 896 842 843 924 768 754 644 684 646
Note: The above table includes the incidence of micro-invasive and invasive cervical cancers.
Source:  National Cancer Statistics Clearing House (AIHW).
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Table 13: Age-specific and age-standardised incidence rates of cervical cancer, by age, Australia,
1988–1999
Age group 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
0–4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.6 0.1 0.1 0.2 0.0 0.2 0.2 0.3 0.2 0.2 0.3 0.0
20–24 2.9 2.4 1.8 1.7 1.3 1.3 2.3 0.4 2.2 1.5 1.5 1.1
25–29 11.1 9.5 8.3 6.7 7.7 5.4 7.4 7.4 6.1 5.9 6.5 7.5
30–34 19.4 19.3 16.1 16.7 14.6 14.4 16.7 15.3 9.4 10.9 11.9 10.3
35–39 21.6 18.9 23.6 21.1 18.6 18.7 18.6 15.4 19.3 13.3 13.5 13.1
40–44 21.8 21.3 22.5 23.5 20.3 19.8 19.9 17.7 17.1 14.7 14.3 14.5
45–49 21.1 20.4 25.3 20.9 18.6 17.6 22.0 16.1 15.9 12.3 16.6 11.4
50–54 16.7 21.1 17.0 21.8 18.2 20.5 19.4 12.2 16.1 13.9 11.3 10.8
55–59 18.4 23.0 22.3 17.6 21.3 20.8 18.9 17.4 15.5 12.1 12.2 10.5
60–64 24.3 23.2 21.0 21.9 20.8 21.1 24.7 19.9 17.1 14.0 14.7 16.3
65–69 31.0 28.9 21.5 25.3 24.6 25.6 26.5 21.7 18.3 15.9 16.0 15.6
70–74 20.2 24.8 24.4 27.6 24.6 21.1 24.3 22.6 18.0 13.7 18.4 13.2
75–79 24.3 23.7 23.1 21.3 23.1 20.0 28.5 21.4 20.9 17.9 16.7 14.6
80–84 27.1 20.9 20.8 24.8 23.1 23.4 23.9 17.4 23.2 17.8 21.4 19.0
85+ 23.0 18.4 21.8 30.0 19.0 17.2 18.8 25.3 17.7 18.8 18.6 12.7
All ages
Crude rate 12.9 12.7 12.5 12.6 11.7 11.4 12.6 10.5 10.1 8.5 9.1 8.2
AS Rate (A) 12.9 12.6 12.4 12.3 11.3 11.0 12.1 10.0 9.5 8.0 8.4 7.7
AS Rate (W) 10.6 10.5 10.2 10.1 9.3 9.1 9.9 8.2 7.8 6.5 6.9 6.3
Ages 20–69 years
Crude rate 17.7 17.4 16.9 16.6 15.3 15.2 16.4 13.5 13.0 11.0 11.5 10.7
AS Rate (A) 17.7 17.4 17.0 16.6 15.3 15.1 16.3 13.4 12.8 10.8 11.2 10.5
AS Rate (W) 17.2 17.0 16.6 16.1 14.9 14.7 15.9 13.0 12.5 10.5 11.0 10.2
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 14a: Number of new cases of cervical cancer by age, states and territories, 1995–1998
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 3 1 2 0 0 0 0 0 6
20–24 11 6 14 3 0 4 0 0 38
25–29 56 41 42 15 16 8 4 3 185
30–34 120 78 75 30 23 15 1 1 343
35–39 155 99 100 38 20 20 9 11 452
40–44 137 117 77 58 24 8 10 6 437
45–49 145 95 65 41 22 9 4 8 389
50–54 117 61 54 20 11 5 5 5 278
55–59 81 61 45 24 13 6 4 2 236
60–64 82 65 38 24 15 10 2 2 238
65–69 85 63 53 26 16 7 1 3 254
70–74 91 54 38 23 21 5 4 2 238
75–79 66 54 39 12 13 6 0 2 192
80–84 47 49 17 14 11 1 3 0 142
85+ 34 36 24 15 6 0 1 0 116
All ages 1,230 880 683 343 211 104 48 45 3,544
Ages 20–69 years 989 686 563 279 160 92 40 41 2,850
Source: National Cancer Statistics Clearing House (AIHW).
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Table 14b: Age-specific rates of cervical cancer, by age, states and territories, 1995–1998
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.4 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.2 0.9 2.7 1.1 0.0 6.3 0.0 0.0 1.4
25–29 5.8 5.6 8.0 5.4 7.5 12.1 7.6 8.1 6.5
30–34 12.3 10.7 14.4 10.7 10.3 21.3 2.0 3.0 11.9
35–39 15.6 13.5 18.8 13.1 8.5 26.3 17.3 35.5 15.4
40–44 14.9 17.1 15.5 21.0 10.9 11.3 19.8 22.2 15.9
45–49 17.0 14.9 13.9 16.4 10.5 13.8 8.2 35.4 15.2
50–54 16.5 11.7 14.1 10.3 6.4 9.3 13.9 31.3 13.3
55–59 14.1 14.5 15.3 15.6 9.3 13.5 16.4 20.3 14.2
60–64 16.1 17.3 15.4 18.5 11.9 25.4 11.0 31.3 16.4
65–69 16.9 17.3 22.3 21.7 12.6 18.5 6.4 67.8 18.0
70–74 19.4 15.8 17.5 21.8 17.0 14.1 27.8 65.9 18.2
75–79 18.3 20.9 23.2 15.0 13.5 21.3 0.0 101.0 19.1
80–84 18.5 26.4 14.5 23.8 16.1 4.9 45.4 0.0 20.0
85+ 16.7 23.1 25.5 30.3 10.6 0.0 20.9 0.0 20.0
All ages
Crude rate 9.8 9.5 10.2 9.7 7.1 10.8 7.7 12.9 9.6
AS rate (A) 9.1 8.7 9.8 9.3 6.4 10.7 7.8 17.9 9.0
95% CI 8.6–9.6 8.1–9.3 9.1–10.6 8.3–10.3 5.5–7.2 8.6–12.8 5.6–10.0 12.7–23.2 8.7–9.3
AS rate (W) 7.5 7.1 8.0 7.6 5.2 8.9 6.3 14.4 7.3
95% CI 7.1–7.9 6.6–7.5 7.4–8.6 6.8–8.4 4.5–5.9 7.2–10.6 4.5–8.1 10.2–18.6 7.1–7.6
Ages 20–69 years
Crude rate 12.5 11.7 13.4 12.5 8.5 15.6 9.9 18.6 12.2
AS rate (A) 12.2 11.5 13.3 12.4 8.4 15.5 9.8 21.9 12.0
95% CI 11.4–13.0 10.6–12.4 12.2–14.4 10.8–13.9 7.1–9.6 12.2–18.9 6.6–13.0 15.2–28.6 11.6–12.5
AS rate (W) 12.0 11.2 12.9 12.0 8.1 15.0 9.7 21.6 11.7
95% CI 11.2–12.7 10.3–12.1 11.9–14.0 10.5–13.5 6.9–9.3 11.8–18.2 6.5–12.8 15.0–28.2 11.3–12.2
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 15a: Number of new cases of cervical cancer, by age, states and territories, 1996–1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 2 1 1 0 0 0 0 0 4
20–24 11 8 15 3 0 5 0 0 42
25–29 61 37 47 13 16 7 5 3 189
30–34 105 58 72 30 26 12 0 2 305
35–39 147 93 102 33 24 24 9 10 442
40–44 130 107 91 52 24 8 5 6 423
45–49 134 90 64 34 25 6 5 8 366
50–54 122 60 54 21 14 5 3 6 285
55–59 64 62 41 19 16 5 4 4 215
60–64 80 60 45 17 18 7 1 2 230
65–69 89 50 50 22 12 4 4 0 231
70–74 83 55 27 22 13 4 3 2 209
75–79 65 45 37 14 14 5 1 2 183
80–84 53 46 21 15 8 2 2 0 147
85+ 35 29 20 13 5 0 1 0 103
All ages 1,181 801 687 308 215 94 43 45 3,374
Ages 20–69 years 943 625 581 244 175 83 36 41 2,728
Source: National Cancer Statistics Clearing House (AIHW).
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Table 15b: Age-specific rates of cervical cancer, by age, states and territories, 1996–1999
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2
20–24 1.3 1.2 3.0 1.1 0.0 8.2 0.0 0.0 1.6
25–29 6.2 5.0 8.8 4.6 7.5 10.6 9.3 7.9 6.5
30–34 10.8 8.0 13.9 10.7 11.8 17.6 0.0 5.9 10.6
35–39 14.5 12.5 18.7 11.2 10.2 31.5 17.2 31.5 14.8
40–44 13.9 15.4 17.9 18.5 10.8 11.2 9.9 21.6 15.1
45–49 15.4 13.9 13.4 13.2 11.7 9.1 10.1 34.0 14.0
50–54 16.3 10.9 13.3 10.2 7.6 8.8 7.7 34.8 12.9
55–59 10.8 14.3 13.2 11.9 11.2 10.9 15.5 37.4 12.5
60–64 15.4 15.7 17.7 12.7 14.2 17.6 5.3 29.6 15.5
65–69 17.9 13.8 21.0 18.2 9.6 10.6 25.3 0.0 16.5
70–74 17.6 16.0 12.3 20.5 10.5 11.3 20.5 62.7 15.8
75–79 17.3 16.6 21.0 16.6 13.9 17.1 9.1 95.1 17.4
80–84 20.5 24.6 17.5 25.3 11.6 9.7 28.7 0.0 20.3
85+ 16.3 17.8 20.1 24.9 8.4 0.0 19.4 0.0 16.8
All ages
Crude rate 9.3 8.5 10.0 8.5 7.2 9.8 6.9 12.6 9.0
AS rate (A) 8.5 7.8 9.7 8.2 6.5 9.7 7.0 15.7 8.4
95% CI 8.0–9.0 7.2–8.3 9.0–10.4 7.3–9.1 5.7–7.4 7.7–11.6 4.9–9.1 11.1–20.3 8.1–8.7
AS rate (W) 7.0 6.4 8.0 6.5 5.4 8.0 5.7 12.8 6.9
95% CI 6.6–7.4 5.9–6.8 7.4–8.6 5.8–7.3 4.7–6.1 6.4–9.6 4.0–7.4 9.1–16.6 6.6–7.1
Ages 20–69 years
Crude rate 11.8 8.5 10.9 8.7 7.5 11.3 7.1 14.7 977.9
AS rate (A) 11.4 10.3 13.5 10.6 9.1 14.1 9.0 18.7 11.3
95% CI 10.7–12.2 9.5–11.1 12.4–14.5 9.2–11.9 7.7–10.4 11.0–17.1 6.1–12.0 13.0–24.4 10.9–11.7
AS rate (W) 11.2 10.1 13.0 10.2 8.9 13.5 8.8 19.0 11.0
95% CI 10.5–11.9 9.3–10.9 12.0–14.1 8.9–11.5 7.5–10.2 10.6–16.4 6.0–11.7 13.2–24.8 10.6–11.5
Note: Rates are expressed per 100,000 women and age standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source: National Cancer Statistics Clearing House (AIHW).
60
Table 16a: Number of new cases of cervical cancer, by histological type for women aged
20–69 years, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 657 688 639 650 610 596 630 546 527 450 484 464
Adenocarcinoma 157 116 149 146 141 141 192 147 148 129 140 126
Adeno-squamous 40 48 50 41 51 47 40 34 40 32 30 23
Other 45 54 61 59 40 59 62 41 39 33 30 33
Total 899 906 899 896 842 843 924 768 754 644 684 646
Micro-invasive 86 87 140 154 151 134 169 176 145 115 116 92
Source: National Cancer Statistics Clearing House (AIHW).
Table 16b: Age-standardised incidence rates for cervical cancer, by histological type for women aged
20–69 years, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 12.9 13.2 12.1 12.0 11.1 10.7 11.1 9.5 9.0 7.5 8.0 7.5
Adenocarcinoma 3.1 0.0 2.8 2.7 2.6 2.5 3.4 2.6 2.5 2.1 2.3 2.0
Adeno-squamous 0.8 0.9 0.9 0.8 0.9 0.8 0.7 0.6 0.7 0.5 0.5 0.4
Other 0.9 1.0 1.1 1.1 0.7 1.1 1.1 0.7 0.7 0.6 0.5 0.5
Micro-invasive 1.1 1.1 1.7 1.8 1.8 1.5 1.9 2.0 1.6 1.2 1.3 1.0
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A).
Source: National Cancer Statistics Clearing House (AIHW).
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Table 17a: Number of new cases of cervical cancer, by histological type for women, all ages, Australia,
1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 777 808 767 793 751 705 780 677 665 548 610 571
Adenocarcinoma 179 136 172 174 157 163 222 173 168 159 165 147
Adeno-squamous 45 53 56 48 56 56 50 39 47 38 35 25
Other 65 74 74 77 60 88 80 68 51 51 50 44
Total 1,066 1,071 1,069 1,092 1,024 1,012 1,132 957 931 796 860 787
Micro-invasive 87 89 145 164 155 139 180 188 153 121 123 95
Source: National Cancer Statistics Clearing House (AIHW).
Table 17b: Age-standardised incidence rates for cervical cancer, by histological type for women, all
ages, Australia, 1988–1999
Histological type 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Squamous 9.4 9.6 8.9 8.9 8.3 7.7 8.3 7.1 6.8 5.5 6.0 5.6
Adenocarcinoma 2.2 0.0 2.0 2.0 1.8 1.8 2.4 1.8 1.7 1.6 1.7 1.4
Adeno-squamous 0.6 0.6 0.7 0.5 0.6 0.6 0.5 0.4 0.5 0.4 0.3 0.2
Other 0.8 0.9 0.8 0.8 0.6 0.9 0.9 0.7 0.5 0.5 0.5 0.4
Micro-invasive 1.1 1.2 1.8 1.9 1.8 1.6 2.0 2.1 1.6 1.3 1.3 1.0
Note: Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A).
Source: National Cancer Statistics Clearing House (AIHW).
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Indicator 8: Incidence by location
Table 18: Number of new cases of cervical cancer, by age and location, 1995–1998 and 1996–1999
Metropolitan Rural Remote
Age group 1995–1998 1996–1999 1995–1998 1996–1999 1995–1998 1996–1999
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 4 2 2 2 0 0
20–24 24 29 14 13 0 0
25–29 136 142 43 40 6 7
30–34 234 209 98 89 11 8
35–39 321 303 110 116 21 23
40–44 329 305 96 101 12 17
45–49 300 277 80 78 8 11
50–54 205 213 67 64 7 8
55–59 167 151 62 59 7 5
60–64 165 158 68 67 5 5
65–69 183 173 59 51 12 7
70–74 182 156 51 48 5 5
75–79 138 133 51 48 3 2
80–84 101 105 38 39 3 3
85+ 89 78 24 23 3 2
All ages 2,577 2,432 863 840 104 102
Ages 20–69
years 2,063 1,959 697 679 90 90
Note: The numbers are presented as 4-year rolling blocks of data.
Source: National Cancer Statistics Clearing House (AIHW).
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Table 19: Age-specific and age-standardised incidence rates for cervical cancer, by age and
location, 1995–1998 and 1996–1999
Metropolitan Rural Remote
Age group 1995–1998 1996–1999 1995–1998 1996–1999 1995–1998 1996–1999
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.2 0.1 0.3 0.3 0.1 0.1
20–24 1.1 1.4 2.6 2.5 0.0 0.0
25–29 6.3 6.5 7.1 6.6 6.5 7.2
30–34 11.1 10.0 14.4 13.3 11.6 8.5
35–39 15.3 14.3 14.6 15.3 24.2 25.5
40–44 16.7 15.2 13.7 14.2 16.6 23.2
45–49 16.2 14.7 12.7 12.1 13.3 16.8
50–54 13.7 13.4 12.5 11.5 13.2 15.2
55–59 14.4 12.6 13.6 12.4 19.5 13.0
60–64 16.4 15.5 16.5 16.0 16.9 16.6
65–69 18.6 17.7 14.6 12.8 51.8 29.9
70–74 19.6 16.7 14.1 13.3 30.5 27.2
75–79 19.2 17.6 18.8 17.0 24.0 15.6
80–84 19.9 20.5 19.9 20.2 33.2 31.7
85+ 21.3 17.7 15.5 14.1 35.9 23.1
All ages
AS rate (A) 9.1 8.4 8.6 8.3 11.8 10.9
95% CI 8.7–9.5 8.1–8.7 8.0–9.2 7.7–8.9 9.5–14.1 8.8–13.0
AS rate (W) 7.4 6.9 7 6.8 9.3 8.8
95% CI 7.1–7.7 6.6–7.2 6.5–7.5 6.3–7.3 7.5–11.1 7.1–10.5
Ages 20–69 years
AS rate (A) 12.1 11.3 11.7 11.3 15.2 14.5
95% CI 11.6–12.6 10.8–11.8 10.8–12.6 10.5–12.1 12.1–18.3 11.5–17.5
AS rate (W) 11.8 11.1 11.4 10.9 14.5 14.0
95% CI 11.3–12.3 10.6–11.6 10.6–12.2 10.1–11.7 11.5–17.5 11.1–16.9
Notes
1. The numbers are presented as 4-year rolling blocks of data.
2. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
Source:  National Cancer Statistics Clearing House (AIHW).
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Indicator 7: Mortality
Table 20: Number of deaths from cervical cancer, by age, Australia, 1981–2000
Age group ’81 ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00
0–4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0
20–24 0 1 1 0 0 2 2 0 1 1 3 0 0 0 0 1 0 3 1 1
25–29 4 7 8 10 6 6 5 3 3 10 5 5 2 6 3 1 2 6 2 4
30–34 12 13 12 13 20 12 15 12 21 14 13 15 11 11 7 13 8 5 6 10
35–39 14 12 18 19 17 16 20 15 18 30 25 19 25 11 16 23 18 19 7 12
40–44 17 22 20 20 18 26 20 24 24 36 19 27 32 28 21 20 16 19 18 14
45–49 18 24 28 26 21 24 19 27 31 36 29 26 23 35 32 30 28 16 25 27
50–54 30 29 26 25 25 25 24 19 27 17 21 13 29 37 26 13 21 24 15 19
55–59 36 41 40 21 31 41 32 41 20 25 25 23 20 26 34 22 24 15 14 19
60–64 46 47 36 41 41 41 28 41 33 34 33 31 25 24 30 21 22 28 15 24
65–69 52 39 49 43 52 50 46 41 54 43 35 25 30 37 37 29 30 19 21 26
70–74 42 35 30 33 43 32 55 34 48 25 37 45 38 33 43 41 36 28 30 37
75–79 40 34 20 29 29 23 29 35 29 32 30 32 28 30 30 38 32 26 26 25
80–84 25 21 22 26 26 23 20 34 24 8 22 35 24 26 27 22 27 26 19 23
85+ 19 18 21 21 29 24 16 17 22 25 32 23 24 24 20 24 30 31 21 26
All ages 354 342 330 327 359 343 329 343 355 337 329 319 311 329 328 296 294 265 220 267
Ages 20–69
years 228 234 238 218 230 242 210 222 231 246 208 184 197 216 207 172 169 154 124 156
Note: Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 21: Age-specific and age-standardised death rates for cervical cancer, by age, Australia, 1981–
2000
Age group ’81 ’82 ’83 ’84 ’85 ’86 ’87 ’88 ’89 ’90 ’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.1 0.1 0.0 0.0 0.3 0.3 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.5 0.2 0.2
25–29 0.6 1.1 1.2 1.5 0.9 0.9 0.7 0.4 0.4 1.4 0.7 0.7 0.3 0.9 0.4 0.1 0.3 0.8 0.3 0.5
30–34 1.9 2.1 1.9 2.1 3.1 1.9 2.3 1.8 3.0 2.0 1.8 2.0 1.5 1.5 0.9 1.8 1.1 0.7 0.8 1.4
35–39 2.8 2.2 3.2 3.2 2.8 2.5 3.1 2.3 2.7 4.6 3.7 2.7 3.6 1.5 2.2 3.1 2.4 2.5 0.9 1.6
40–44 4.1 5.1 4.5 4.3 3.7 5.4 3.7 4.1 3.9 5.9 2.9 4.3 5.0 4.3 3.1 2.9 2.3 2.7 2.5 1.9
45–49 4.9 6.4 7.6 6.9 5.2 5.7 4.4 6.3 6.9 7.6 5.8 4.9 3.9 5.9 5.2 4.7 4.4 2.5 3.8 4.0
50–54 8.0 7.9 7.2 7.0 7.1 6.8 6.4 4.9 7.1 4.2 5.0 3.0 6.8 8.2 5.6 2.6 3.9 4.2 2.5 3.1
55–59 9.8 11.1 10.7 5.5 8.4 11.1 8.8 11.3 5.4 6.8 7.1 6.2 5.2 6.9 8.7 5.3 5.7 3.5 3.1 4.0
60–64 14.3 14.2 10.6 11.5 11.3 11.2 7.7 11.1 9.0 9.3 9.0 8.6 7.1 6.6 8.5 5.8 6.1 7.6 4.0 6.2
65–69 18.2 13.5 16.8 14.9 17.8 16.4 14.6 12.5 15.7 12.4 10.0 7.2 8.5 10.5 10.5 8.3 8.5 5.4 6.1 7.5
70–74 18.7 15.0 12.5 13.2 16.6 12.3 20.5 12.8 18.1 9.4 13.2 15.4 12.6 10.5 13.4 12.6 11.0 8.5 9.1 11.2
75–79 26.0 21.3 11.6 16.7 16.0 11.8 14.8 17.1 13.7 14.7 13.5 14.1 12.4 13.3 13.0 15.7 12.5 9.7 9.2 8.7
80–84 24.0 19.6 19.9 23.4 22.9 19.0 15.8 26.6 17.6 5.6 14.8 23.3 14.9 15.8 15.9 12.2 15.1 14.4 10.6 12.3
85+ 24.9 22.7 25.6 24.7 33.1 24.9 16.1 16.7 20.9 23.2 29.4 19.5 19.3 18.4 14.6 16.6 20.1 19.9 12.7 15.2
All ages
AS rate (A) 6.2 5.9 5.5 5.4 5.7 5.4 5.0 5.1 5.2 4.9 4.6 4.3 4.1 4.3 4.2 3.7 3.5 3.1 2.5 3.0
As rate (W) 5.3 5.2 5.0 4.7 4.9 4.8 4.4 4.4 4.6 4.4 4.0 3.6 3.6 3.8 3.7 3.1 3.0 2.7 2.2 2.7
Ages 20–69 years
AS rate (A) 5.0 5.1 5.1 4.7 4.8 4.9 4.2 4.3 4.4 4.6 3.8 3.3 3.5 3.8 3.6 2.9 2.8 2.5 2.0 2.5
As rate (W) 5.0 5.1 5.1 4.6 4.7 4.9 4.1 4.3 4.4 4.5 3.8 3.3 3.5 3.8 3.6 2.8 2.8 2.5 2.0 2.5
Notes
1. Rates for all ages are based on data for women aged 15 years and over.
2. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 Population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 22: Number of deaths from cervical cancer, by age, states and territories, 1993–1996
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 1 0 0 0 0 0 0 0 1
20–24 0 0 1 0 0 0 0 0 1
25–29 2 3 5 0 0 0 2 0 12
30–34 13 11 9 6 2 1 0 0 41
35–39 25 16 16 8 6 1 0 2 74
40–44 38 25 16 12 4 4 2 1 101
45–49 50 21 17 16 5 7 2 4 121
50–54 41 18 23 11 4 4 3 3 106
55–59 32 23 17 13 8 7 1 2 102
60–64 37 19 14 12 9 6 2 2 100
65–69 44 40 22 15 7 5 0 2 134
70–74 57 41 25 14 12 7 1 0 156
75–75 42 28 33 7 10 4 2 1 127
80–84 31 27 16 9 12 2 1 1 99
85+ 30 26 9 10 9 4 2 0 90
All ages 445 297 220 130 86 51 18 18 1,264
Ages 20–69
years 283 173 137 91 44 34 12 16 791
Notes
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 23: Age-specific and age-standardised death rates for cervical cancer, by age, states and
territories, 1993–1996
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
25–29 0.2 0.4 1.0 0.0 0.0 0.0 3.9 0.0 0.4
30–34 1.3 1.5 1.7 2.1 0.8 1.3 0.0 0.0 1.4
35–39 2.7 2.2 3.1 2.8 2.6 1.3 0.0 6.7 2.6
40–44 4.3 3.7 3.3 4.5 1.8 5.7 3.9 3.8 3.8
45–49 6.1 3.4 3.8 6.8 2.4 10.9 4.2 19.0 5.0
50–54 6.5 3.8 6.8 6.3 2.5 8.0 9.5 21.6 5.7
55–59 5.9 5.6 6.2 8.9 5.9 16.2 4.4 23.1 6.5
60–64 7.4 5.0 5.7 9.4 7.0 15.0 11.5 33.7 7.0
65–69 8.7 10.9 9.2 12.5 5.2 12.8 0.0 48.0 9.5
70–74 12.4 12.4 11.7 13.5 9.7 19.3 7.2 0.0 12.3
75–75 12.5 11.8 21.4 9.2 10.9 14.5 22.0 55.1 13.6
80–84 13.0 15.5 14.4 15.7 18.0 10.2 16.6 108.6 14.7
85+ 16.5 18.6 10.5 22.1 17.3 28.1 47.2 0.0 17.2
All ages
AS rate (A) 4.6 4.1 4.7 5.4 3.4 6.9 4.9 14.4 4.5
95% CI 4.1–5.0 3.6–4.5 4.0–5.2 4.3–6.2 2.7–4.1 4.9–8.7 2.6–7.2 7.2–22.5 4.3–4.8
As rate (W) 4.2 3.6 4.2 5.0 3.0 6.6 4.4 13.0 4.1
95% CI 3.8–4.6 3.2–4.0 3.6–4.7 4.0–5.8 2.3–3.6 4.7–8.5 2.3–6.6 7.0–19.7 3.9–4.3
Ages 20–69 years
AS rate (A) 3.5 3.0 3.5 4.4 2.3 5.7 3.2 11.8 3.4
95% CI 3.1–4.0 2.5–3.4 2.9–4.0 3.4–5.2 1.6–2.9 3.7–7.5 1.5–5.2 5.8–18.8 3.2–3.7
As rate (W) 3.5 2.9 3.5 4.4 2.3 5.8 3.5 12.0 3.4
95% CI 3.1–4.0 2.4–3.3 2.8–3.9 3.3–5.2 1.6–3.0 3.8–7.7 1.6–5.6 6.0–19.0 3.2–3.7
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 Population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
68
Table 24: Number of deaths from cervical cancer, by age, states and territories, 1997–2000
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0 0 0 0 0 0 0 0 0
5–9 0 0 0 0 0 0 0 0 0
10–14 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0
20–24 2 2 1 0 0 0 0 0 5
25–29 1 4 5 2 1 0 1 0 14
30–34 7 5 5 8 3 1 0 0 29
35–39 21 12 10 6 2 3 0 2 56
40–44 26 14 14 7 0 1 3 2 67
45–49 33 22 17 9 10 0 3 2 96
50–54 34 12 18 5 4 3 2 1 79
55–59 26 12 18 9 3 2 1 1 72
60–64 25 19 23 8 5 8 0 1 89
65–69 37 14 16 12 9 4 4 0 96
70–74 45 36 21 14 8 4 1 2 131
75–79 39 28 18 7 9 4 2 2 109
80–84 34 27 12 12 7 2 0 1 95
85+ 42 24 16 17 5 3 1 0 108
All ages 372 231 194 116 66 35 18 14 1,046
Ages 20–69
years 212 116 127 66 37 22 14 9 603
Notes
1. Numbers were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
Source: AIHW Mortality Database.
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Table 25: Age-specific and age-standardised death rates for cervical cancer, by age, states and
territories, 1997–2000
Age group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.2 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.2
25–29 0.1 0.5 0.9 0.7 0.5 0.0 1.9 0.0 0.5
30–34 0.7 0.7 1.0 2.9 1.4 1.5 0.0 0.0 1.0
35–39 2.1 1.6 1.8 2.0 0.9 4.0 0.0 6.3 1.9
40–44 2.7 2.0 2.7 2.5 0.0 1.4 6.0 7.2 2.4
45–49 3.8 3.4 3.5 3.4 4.7 0.0 6.2 8.5 3.7
50–54 4.4 2.1 4.2 2.3 2.1 5.1 4.9 5.5 3.4
55–59 4.3 2.7 5.6 5.5 2.0 4.3 3.7 9.0 4.1
60–64 4.8 4.9 8.8 5.9 3.9 19.8 0.0 14.3 5.9
65–69 7.5 3.9 6.7 9.9 7.3 10.6 25.0 0.0 6.9
70–74 9.6 10.5 9.5 12.9 6.5 11.4 6.9 61.2 9.9
75–75 10.0 9.9 9.8 8.0 8.6 13.3 16.9 96.3 10.0
80–84 13.1 14.5 9.8 20.4 10.1 9.7 0.0 78.3 13.1
85+ 18.7 14.1 15.2 30.9 8.0 17.3 18.0 0.0 16.8
All ages
AS rate (A) 3.4 2.9 3.6 4.2 2.5 4.5 4.4 11.1 3.4
95% CI 3.1–3.8 2.5–3.3 3.1–4.1 3.4–4.9 1.9–3.1 3.0–6.1 2.5–6.5 4.6–18.1 3.2–3.6
As rate (W) 3.1 2.5 3.4 3.6 2.2 4.1 4.0 8.5 3.0
95% CI 2.7–3.4 2.2–2.9 2.9–3.9 2.9–4.3 1.7–2.8 2.7–5.7 2.3–6.1 4.1–13.5 2.8–3.2
Ages 20–69 years
AS rate (A) 2.5 1.9 2.9 2.9 1.8 3.5 3.7 4.4 2.4
95% CI 2.1–2.9 1.5–2.2 2.3–3.3 2.2–3.6 1.3–2.4 2.1–5.1 1.8–6.0 1.6–7.6 2.2–2.6
As rate (W) 2.5 1.9 2.9 2.8 1.8 3.5 3.6 4.5 2.4
95% CI 2.1–2.8 1.5–2.2 2.4–3.4 2.1–3.5 1.3–2.4 2.0–5.0 1.9–5.8 1.7–7.8 2.2–2.6
Notes
1. The age-standardised rates were averaged over 4 years to smooth annual variations that may occur in the smaller states and territories.
2. Deaths were derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 Population (A) and the World Standard
Population (W).
Source: AIHW Mortality Database.
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Table 26: Number of deaths from cervical cancer, by age and location, 1993–1996 and 1997–2000
Metropolitan Rural Remote
Age group 1993–1996 1997–2000 1993–1996 1997–2000 1993–1996 1997–2000
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 1 0 0 0 0 0
20–24 1 4 0 1 0 0
25–29 9 8 2 5 1 1
30–34 25 20 15 7 1 2
35–39 53 39 17 16 4 1
40–44 67 48 31 15 3 4
45–49 83 75 29 18 8 3
50–54 73 59 29 19 4 1
55–59 71 49 27 19 4 4
60–64 66 58 28 30 6 1
65–69 84 65 43 27 7 4
70–74 115 87 38 39 3 5
75–75 90 78 36 29 1 2
80–84 70 71 28 19 1 5
85+ 67 74 24 32 0 2
All ages 873 735 349 276 42 35
Ages 20–69
years 531 425 222 157 37 21
Notes
1. Deaths were derived from place of usual residence and by year of registration.
2. The number of deaths is presented as 4-year rolling blocks of data.
Source: AIHW Mortality Database.
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Table 28: Number of deaths from cervical cancer, by age and Indigenous status, 1995–1998,
1996–1999 and 1997–2000
Indigenous Non-Indigenous
Age group 1995–1998 1996–1999 1997–2000 1995–1998 1996–1999 1997–2000
0–4 0 0 0 0 0 0
5–9 0 0 0 0 0 0
10–14 0 0 0 0 0 0
15–19 0 0 0 0 0 0
20–24 0 0 0 0 0 0
25–29 0 1 1 5 5 6
30–34 1 1 2 8 8 13
35–39 3 2 2 19 11 15
40–44 4 5 5 9 19 17
45–49 5 2 5 19 21 30
50–54 0 1 0 14 19 21
55–59 1 1 2 26 17 24
60–64 4 2 2 22 27 34
65–69 4 2 3 18 20 31
70–74 2 3 4 23 34 35
75+ 1 3 3 75 76 91
All ages 25 23 29 235 256 317
Ages 20–69
years 22 17 22 138 147 191
Notes
1. Deaths were derived from place of usual residence and by year of registration.
2. The number of deaths is presented as 4-year rolling blocks of data.
3. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
Source: AIHW Mortality Database.
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Table 29: Age-specific and age-standardised death rates for cervical cancer, by age and Indigenous
status, 1995–1998, 1996–1999 and 1997–2000
Indigenous Non-Indigenous
Age group 1995–1998 1996–1999 1997–2000 1995–1998 1996–1999 1997–2000
0–4 0.0 0.0 0.0 0.0 0.0 0.0
5–9 0.0 0.0 0.0 0.0 0.0 0.0
10–14 0.0 0.0 0.0 0.0 0.0 0.0
15–19 0.0 0.0 0.0 0.0 0.0 0.0
20–24 0.0 0.0 0.0 0.0 0.0 0.0
25–29 0.0 2.8 2.5 0.8 0.7 0.7
30–34 3.8 3.3 5.6 1.2 1.1 1.5
35–39 14.0 7.8 6.7 2.8 1.4 1.6
40–44 23.5 24.5 20.7 1.4 2.5 1.9
45–49 39.2 13.0 27.1 3.2 2.9 3.5
50–54 0.0 8.5 0.0 2.9 3.1 2.8
55–59 14.5 12.5 21.4 6.9 3.7 4.3
60–64 72.1 31.0 27.0 6.8 6.9 7.3
65–69 98.9 42.1 55.3 5.8 5.5 7.3
70–74 81.9 101.8 115.6 7.9 9.9 8.8
75+ 30.6 79.7 70.6 14.7 12.1 12.1
All ages
AS Rate (A) 26.5 17.4 19.7 2.6 2.3 2.5
95% CI 15.8–38.0 9.2–26.4 11.5–28.8 2.2–3.0 2.0–2.7 2.2–2.8
As Rate (W) 22.9 16.7 18.2 3.2 2.8 3.0
95% CI 13.8–32.8 9.3–24.5 11.7–25.6 2.7–3.6 2.5–3.2 2.7–3.3
Ages 20–69 years
AS Rate (A) 17.5 10.6 11.3 2.3 1.9 2.1
95% CI 8.8–26.5 5.2–17.1 6.2–17.1 1.9–2.7 1.6–2.3 1.7–2.4
As Rate (W) 20.5 11.4 12.9 2.6 2.3 2.5
95% CI 11.5–29.4 6.0–17.8 7.6–18.8 2.1–3.0 1.9–2.6 2.1–2.8
Notes
1. The age-standardised rates are presented as 4-year rolling blocks of data.
2. Deaths derived from place of usual residence and by year of registration.
3. Rates for all ages are based on data for women aged 20 years and over.
4. Rates are expressed per 100,000 women and age-standardised to the Australian 1991 population (A) and the World Standard
Population (W).
5. Only Queensland (from 1998), South Australia, Western Australia and the Northern Territory have Indigenous death registration data
considered to be of a publishable standard.
Source: AIHW Mortality Database.
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Appendix A Cervical cancer: symptoms, detection and treatment
Cervical cancer affects the cells of the cervix, which is the lower part of the womb or uterus as it
joins the inner end of the vagina. Like other cancers, cervical cancer is a disease where normal
cells change, begin to multiply out of control, and form a growth or tumour. The cancer may
arise from the squamous cells at the transformation zone where the squamous cells on the
outside of the cervix join the columnar cells in the lining of the cervical canal (squamous cell
carcinoma) or from the cells in the cervical canal (adenocarcinoma). Over two-thirds of cervical
cancers are squamous cell carcinomas, which are most easily detected on the Pap smear, while
about 20% are adenocarcinomas. If not detected early, the tumour can invade local tissue and
spread or metastasise to other parts of the body. The main symptoms of cervical cancer are
unusual bleeding from the vagina, and very rarely an unusual vaginal discharge. However,
these symptoms are quite common and may not be due to cancer.
A cervical cancer may take 10 or more years to develop, but before this the cells may show pre-
cancerous changes. These early changes can be detected by a Pap smear which is described in
more detail below, and with early treatment of these abnormalities, cervical cancer can be
prevented. The most recent classification of these pre-cancerous lesions has two levels of
severity: low-grade epithelial abnormalities (LGEA) and high-grade epithelial abnormalities
(HGEA). An earlier classification described various grades of cervical intra-epithelial neoplasia
(CIN). Low-grade abnormalities include minor changes in squamous cells and CIN 1 while
high-grade abnormalities include CIN 2, CIN 3, squamous carcinoma-in-situ, adenocarcinoma
in situ and invasive carcinoma (squamous or adenocarcinoma).
The Pap smear is the most common way to detect pre-cancerous changes, which rarely cause
any symptoms. The test involves a doctor inserting a speculum into the vagina and gently
scraping the surface of the cervix. This process collects cells that are transferred onto a slide or
into a special liquid, which is then sent to a pathology laboratory for assessment. Pap smears
are offered by general practitioners, gynaecologists, family planning clinics, women’s health
centres, hospital outpatient clinics and in some circumstances specially trained nurses.
If the Pap smear shows an abnormality, the woman may be advised to have a repeat Pap smear
if the abnormality is low-grade or she may be advised to have a colposcopy. With colposcopy, a
doctor is able to look directly at the cervix under magnification using an instrument called a
colposcope. Using a special stain the doctor can highlight any suspicious area, which may be
pre-cancerous or cancerous. The doctor will then take a tissue sample (a biopsy) of the
suspicious area for further examination by the pathologist.
Pre-cancerous changes can easily be treated to prevent the progression to cervical cancer. The
type of treatment depends on whether the change observed is low or high grade, the woman’s
age and general health, whether she wants to have children, and her preferences.
• There is a range of treatments for pre-cancerous changes, including laser treatment, loop
excision (LLETZ), cryosurgery (cold coagulation), electrodiathermy, or cone biopsy, (either
by laser or by scalpel). In a small number of instances, a hysterectomy may be necessary.
For invasive cancer, a cone biopsy or hysterectomy is generally performed. If the cancer cells
are only detected on the surface of the cervix, it may be treated by a cone biopsy. If it has
invaded deeper into the cervix, a hysterectomy is generally performed. In advanced cases, a
radical hysterectomy is needed to remove the cervix and uterus along with a margin of tissue
around the cervix and lymph nodes from the pelvis. Radiotherapy is sometimes used as well as
surgery, and for more advanced cases it may be used on its own.
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Appendix B: Data sources and limitations
All data used in this report are based on calendar years. Data are derived from multiple sources
and are summarised below.
Table B1: Cervical cancer screening indicators data sources
Indicator Description Data source
1 Participation rate for cervical cancer screening National Cervical Screening Program
2 Early re-screening National Cervical Screening Program
3 Low-grade abnormality detection National Cervical Screening Program
4 High-grade abnormality detection National Cervical Screening Program
5 Incidence of micro-invasive cervical cancer
(ICD-10 C53, Histology 8076) National Cancer Statistics Clearing House
6, 8 Incidence of squamous, adenocarcinoma, adeno-
squamous and other cervical cancer (ICD-10 C53) National Cancer Statistics Clearing House
7, 9, 10 Mortality from cervical cancer (ICD-9 180)
For 1999 data (ICD10 C53) AIHW Mortality Database
Population data
The Australian Bureau of Statistics estimated resident female population has been used to
calculate incidence and mortality rates. Participation rates were calculated using the average of
the 1998 and 1999 estimated resident female population (see Appendix D for tables). There may
be some variation in published participation rates because national rates use estimated resident
population data in the denominator whereas local data analysis may use census counts. The
denominator population used to calculate cervical screening participation rates has been
adjusted by the estimated proportion of women who have had a hysterectomy by age. These
data were derived from the 1995 National Health Survey, and are tabled in Appendix D.
The age-standardised rates in this publication are calculated using the total estimated 1991
mid-year Australian resident population. Where appropriate, rates are also standardised to the
World Standard Population for international comparison. Both the Australian and World
Standard Populations are in Appendix D.
Indigenous mortality data
Due to the difficulties of Indigenous identification, mortality data used in Indicator 10 are
based on deaths in Queensland (for 1998, 1999 and 2000), Western Australia, South Australia
and the Northern Territory only.
Other data limitations
• Hysterectomy fractions are calculated using national data derived from the National Health
Survey using aggregate data that do not necessarily reflect variation at the state or territory
level.
• Participation rates will be underestimates to the extent that a small percentage of women
choose to opt-off local registers and have been excluded from the statistics in this report.
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• The participation numbers for states and territories other than Western Australia and
Australian Capital Territory, and the Australian totals, may be over-estimated because of
double counting of some women in registers. This may be the result of difficulty in
identifying state or territory of residence for women in border areas and the inclusion in
registers of women resident overseas.
• Participation rates published by state and territory programs may differ from those in this
publication because of variation in denominators used.
Appendix C: Methods
This section describes the methods employed to calculate the estimates presented in the tables
in the body of this publication.
Crude rates
A crude rate is defined as the number of events over a specified period of time (e.g. a year)
divided by the total population. For example, a crude cancer incidence rate is similarly defined
as the number of new cases of cancer in a specified period of time divided by the population at
risk. Crude death rates and cancer incidence rates are expressed in this report as rates per
100,000 population. Crude participation rate is expressed as a percentage.
Age-specific rates
Age-specific rates are calculated by dividing the number of cases occurring in each specified
age group by the corresponding population in the same age group expressed as a percentage or
a rate per 1,000 or 100,000 population. This rate may be calculated for particular age and sex
groupings, e.g.
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tes are adjusted for age to facilitate comparisons between populations that have different age
ructures, e.g. between youthful and ageing communities. There are two different methods
mmonly used to adjust for age. In this publication we use direct standardisation in which
e-specific rates are multiplied against a constant population (the Australian 1991 Population
andard unless otherwise specified). This effectively removes the influence of age structure on
e summary rate that is described as the age-standardised rate. The method may be used for
e calculation of participation, incidence and mortality rates. The method used for this
lculation comprises three steps.
ep 1: Calculate the age-specific rate (as shown above) for each age group.
ep 2: Calculate the expected number of cases in each 5-year age group by multiplying the
e-specific rates by the corresponding standard population and dividing by 100,000, giving
u the expected number of cases.
ep 3: Sum the expected number of cases in each age group to give the age-standardised rate.
ivide this sum by the total of the standard population and multiply by 100,000.
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Confidence intervals
Population numbers for incidence, mortality and screening have a natural level of variability
for a single year above and below what might be expected in the mean over many years. The
percentage variability is small for large population numbers but high for small numbers such
as mortality in a young age group. One measure of the likely difference is the standard error,
which indicates the extent to which a population number might have varied by chance in only
one year of data.
In the 95% confidence interval there are about 19 chances in 20 that the difference will be less
than two standard errors.
The 95% confidence intervals in this report were calculated using the software package
Palisade @risk (http://www.palisade.com). These calculations were based on 1,000 simulations
using a binomial or Poisson distribution with the observed data to calculate the distribution
parameters.
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Appendix D: Population data
Table D1: Australian Standard Population and World Standard Population
Age group World Standard Population (W) Australian 1991 Population Standard (A)
0–4 12,000 1,271,703
5–9 10,000 1,272,208
10–14 9,000 1,241,619
15–19 9,000 1,364,074
20–24 8,000 1,396,764
25–29 8,000 1,399,663
30–34 6,000 1,425,735
35–39 6,000 1,328,387
40–44 6,000 1,294,271
45–49 6,000 1,029,145
50–54 5,000 846,934
55–59 4,000 725,950
60–64 4,000 736,868
65–69 3,000 671,390
70–74 2,000 510,755
75–79 1,000 384,495
80–84 500 229,828
85+ 500 154,247
Total 100,000 17,284,036
Sources: Australian Bureau of Statistics 1993 (for Australian Standard Population);
Doll and Smith 1982 (for World Standard Population).
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Table D2: Hysterectomy fractions for women aged 15–80+ years,
Australia, 1995
Age group % of women who have not had a hysterectomy
18–19 98.4
20–24 99.8
25–29 99.3
30–34 98.0
35–39 91.9
40–44 85.2
45–49 79.1
50–54 68.5
55–59 68.5
60–64 67.8
65–69 68.8
70–74 66.8
75–79 66.8
80+ 61.5
Total 84.3
Source: ABS 1995.
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Table D3: Estimated resident female populations, by age, states and territories, June 1999
Age
group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 210,825 149,345 117,830 61,742 46,022 15,373 10,369 8,481 620,101
5–9 217,147 157,607 124,506 64,778 48,311 16,591 10,727 8,378 648,219
10–14 213,517 155,122 122,073 66,783 48,963 17,091 10,794 7,465 641,992
15–19 214,180 157,811 125,527 65,940 49,288 16,951 11,568 7,015 648,380
20–24 218,587 167,569 125,120 67,885 48,428 14,750 13,024 7,837 663,257
25–29 248,403 186,122 136,228 71,363 52,440 16,005 13,157 9,524 733,363
30–34 236,656 181,447 128,549 69,303 53,023 16,123 12,164 8,579 706,004
35–39 254,383 187,302 139,312 74,660 58,441 18,625 12,635 8,055 753,568
40–44 238,135 176,533 130,717 71,804 56,080 17,940 12,380 6,971 710,706
45–49 220,757 164,621 122,514 66,279 53,683 16,750 12,104 6,019 662,831
50–54 198,358 147,675 110,532 56,265 48,969 15,085 10,507 4,711 592,163
55–59 154,145 113,036 82,604 41,983 37,196 11,878 6,866 2,900 450,656
60–64 131,505 96,830 66,557 34,641 32,448 10,136 4,947 1,767 378,852
65–69 121,817 90,079 59,234 30,379 30,570 9,450 4,002 1,178 346,720
70–74 117,014 85,765 55,803 27,180 30,571 8,771 3,655 818 329,585
75–79 100,326 73,381 46,982 22,832 26,932 7,774 3,118 538 281,885
80–84 121,721 89,214 57,646 28,481 33,150 9,534 3,227 592 343,574
Total 3,217,476 2,379,459 1,751,734 922,298 754,515 238,827 155,244 90,828 9,511,856
Source: AIHW Population Database based on estimated resident population data compiled by ABS.
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Table D4: Estimated resident female populations, states and territories, June 2000
Age
group NSW Vic Qld WA SA Tas ACT NT Australia
0–4 209,570 148,031 117,729 61,561 45,105 14,905 10,325 8,534 615,872
5–9 216,795 157,690 125,521 64,597 48,156 16,421 10,517 8,385 648,246
10–14 214,943 156,611 123,876 67,245 48,752 16,800 10,683 7,634 646,729
15–19 216,913 160,267 127,720 67,397 49,936 17,112 11,511 7,063 658,049
20–24 219,669 169,075 125,263 68,444 47,967 14,484 13,098 7,800 665,858
25–29 249,540 185,647 136,576 71,540 51,294 15,619 13,084 9,306 732,705
30–34 238,393 183,782 130,487 69,712 52,481 16,058 12,183 8,888 712,133
35–39 251,930 186,833 139,889 74,320 57,412 18,059 12,419 8,103 749,138
40–44 242,164 179,754 134,059 72,796 57,102 18,108 12,421 7,077 723,621
45–49 223,345 167,055 124,623 67,886 53,884 16,915 12,057 6,170 672,047
50–54 204,510 153,221 114,902 59,095 50,423 15,571 10,857 4,960 613,603
55–59 160,386 117,391 88,137 43,873 38,973 12,256 7,321 3,119 471,505
60–64 133,989 99,251 69,300 35,667 33,043 10,502 5,188 1,850 388,816
65–69 120,637 89,476 59,746 30,668 30,146 9,427 4,091 1,237 345,436
70–74 117,083 86,092 56,242 27,745 30,371 8,810 3,684 859 330,898
75–79 101,838 74,602 48,218 22,980 27,379 7,808 3,211 532 286,572
80+ 126,622 92,989 60,220 29,796 34,403 9,943 3,462 632 358,075
Total 3,248,327 2,407,767 1,782,508 935,322 756,827 238,798 156,112 92,149 9,619,303
Source: AIHW Population Database based on estimated resident population data compiled by ABS.
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Glossary
Ablative therapy: the destruction of cells on the surface of the cervix using laser therapy,
chemicals or diathermy.
ABS: Australian Bureau of Statistics.
Adjuvant: enhancing or administered to enhance the effectiveness of a treatment or
substance.
AHMAC: Australian Health Ministers’ Advisory Council.
AIHW: Australian Institute of Health and Welfare.
AS rate: age-standardised rate.
ASGC: Australian Standard Geographical Classification: the classification designed by the
ABS to define the geography of Australia.
Basement membrane: the delicate, non-cellular layer on which an epithelium is seated. The
epithelium forms the surface portion of the skin and lines hollow organs and all passages of
the respiratory, digestive and genito-urinary systems.
Benign: not malignant.
Cancer (malignant neoplasm): a term used to describe one of several diseases which result
when the process of cell division, by which tissues normally grow and renew themselves,
becomes uncontrolled and leads to the development of malignant cells. These cancer cells
multiply in an uncoordinated way, independently of normal growth control mechanisms, to
form a tumour. This tumour may expand locally by invasion or systemically by metastasis
via the lymphatic or vascular systems. If left untreated most malignant tumours will
eventually result in death.
Cancer death: a death where the underlying cause is indicated as cancer. Persons with cancer
dying of other causes are not counted in the death statistics in this publication.
CIN (cervical intraepithelial neoplasia): Squamous cell carcinoma of the cervix is mostly
preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as
cervical intraepithelial neoplasia (CIN) graded as CIN I (mild dysplasia), CIN II (moderate
dysplasia) and CIN III (severe dysplasia and carcinoma in situ). CIN usually occurs at least a
decade before cervical cancer. If CIN remains untreated, some women will develop cervical
cancer while others will progress to invasive cervical cancer, despite treatment (Jelfs 1995).
Colposcopy: an examination of the lower genital tract with a magnifying instrument called a
colposcope. This method of conservative evaluation allows the clinician to more accurately
assess the cytologic abnormality by focussing on the areas of greatest cellular abnormality
and by sampling them with a punch biopsy to attain diagnosis.
DHA: Commonwealth Department of Health and Ageing (since November 2001).
DHAC: Commonwealth Department of Health and Aged Care (October 1998 to
November 2001).
DHFS: Commonwealth Department of Health and Family Services (from 1996 to
October 1998).
DHSH: Commonwealth Department of Human Services and Health (1994–1996).
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Epidemiology: the quantitative study of the distribution and determinants of health-related
states and events in populations, and the application of this study to the control of health
problems.
HGA: high-grade abnormalities as defined for this report include CIN 1/2, CIN 2, CIN 3 or
adenocarcinoma in situ.
HPV: Human papilloma virus.
Hysterectomy: refers to the surgical procedure whereby all or part of the uterus is removed.
Hysterectomy fractions: the proportion of women who have had their uterus removed by
hysterectomy.
ICD-10: International Classification of Disease—a coding system used to identify the primary
site of the malignancy. This classification is in its tenth revision.
Incidence: see new cancer case.
Intraepithelial: refers to that area within the layer of cell tissues forming the epidermis of a
body cavity. These cells comprise contiguous cells having minimum intercellular substance.
Invasive cancer: a tumour whose cells have a tendency to invade healthy or normal tissues.
LGA: low-grade abnormalities include atypia, warty atypia (human papilloma virus (HPV)
effect), possible CIN, equivocal CIN, CIN 1 or endocervical dysplasia not otherwise specified
(NOS).
Lymph node: masses of lymphatic tissue, often bean-shaped, that produce lymphocytes and
through which lymph filters. These are located throughout the body.
Metastasis: the process by which a disease is transferred from one part of the body to
another, for example, via the lymphatic system or the bloodstream.
Mortality: see cancer death
New cancer case: a person who has a new cancer diagnosed for the first time. One person
may have more than one cancer and therefore may be counted twice in incidence statistics if
it is decided that the two cancers are not of the same origin. This decision is based on a series
of principles set out in more detail in a publication by Jensen et al. (1991).
NOS: i.e. otherwise specified.
Pap smear: a test prepared for the study of exfoliated cells from the cervix (refer to
Appendix A Cervical cancer: symptoms, detection and treatment).
Post-partum: following childbirth.
Radiation therapy: the treatment of disease with any type of radiation, most commonly with
ionising radiation, such as X-rays, beta rays and gamma rays.
RRMA: Rural, Remote and Metropolitan Areas classification.
Screening: the performance of tests on apparently well people in order to detect a medical
condition at an earlier stage than would otherwise be the case.
Sensitivity: the proportion of individuals with the disease whom the screening test labels
positive.
Stroma: the supporting framework of an organ.
The Institute: the Australian Institute of Health and Welfare.
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